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Abstract  
 
Psoriasis is a chronic autoimmune skin condition. Interleukin 17A (IL-17A) is a 
pro-inflammatory cytokine with a key role in the pathogenesis of this disease. 
Antibodies targeting IL-17A have shown superior efficacy compared with other 
psoriasis treatments, and long-term studies have demonstrated these to be safe 
in humans. Nevertheless, despite the excellent safety and efficacy record of 
these monoclonal antibodies in psoriasis treatment, patient access to these new 
first line therapies is restricted for financial reasons. Replacing passive 
immunisation by therapeutic vaccination targeting IL-17A has the potential to 
overcome this serious impediment and address this currently unmet medical 
need. A series of experiments were performed in mice as proof of concept for 
the primary pharmacodynamic action of such a vaccine and in order to obtain 
informative data on the principle pharmacokinetic parameters. We used the 
most widely employed in vivo model for psoriasis, the topical imiquimod 
challenge. This elicits a psoriasis-like skin disease, which has been extensively 
characterised and, importantly, involves IL-17A signaling. A concern with auto-
vaccines is safety. The data demonstrate that the vaccine-induced antibody titre 
is reversible, that it can be boosted by a variety of immunisation schedules, and 
that antibody titres are not affected by an imiquimod-induced psoriasis-like 
inflammatory flare. Furthermore, the antibody response generated was highly 
specific, as no significant antibodies reactive to the most closely related isoform, 
IL-17F, were detectable. Most importantly, we conducted a head-to-head 
comparison with a monoclonal antibody targeting IL-17A, which is known to be 
highly effective against psoriasis, to assess efficacy. The results show that in 
mice the vaccine effects are of equal efficacy to injected IL-17A monoclonal 
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antibodies. These findings support the rationale for clinical development of the 
vaccine.  
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Introduction  
 
This introduction will cover the fundamental histology, genetics and immunology 
of psoriasis. The relationship between interleukin-17 and development of 
psoriasis will be covered in detail. The mechanism of action of biological agents, 
in particular those which target interleukin-17 and supporting pathways will be 
explored. Past approaches for IL-17 vaccination use in inflammatory disorders 
and vaccine development in psoriasis will supplement the above and be 
integrated as far as relevant for this thesis. This introduction will not cover other 
treatments available for psoriasis. It will not focus on the pathogenesis of 
psoriatic arthritis or other associated co-morbidities (1-5).  
 
1.1 The Skin  
The skin is the largest organ of the human body covering approximately 1-2m2 
surface area and accounts for 16% of an adult’s body weight. The skin is in 
direct contact with the external environment and represents the primary defence 
layer against harmful pathogens and microbes. It also has essential functions in 
immune surveillance, thermoregulation, vitamin D synthesis, sensory function 
and retention of moisture (6, 7). There are significant differences in human skin 
based on its location. Skin found on the palms and soles is characterised by a 
thickened epidermis, compared to other areas of skin elsewhere  which have 
both sebaceous glands and hair follicles. The many cell types form the complex 
architecture which can be considered as three distinct skin layers: epidermis, 
dermis and subcutaneous layer (8). 
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1.1.1 Layers of the skin  
The epidermis is the uppermost of the skin layers and is completely avascular, 
relying on nourishment via diffusion from the dermis. It can be further 
categorised into the keratin layer, granular layer, prickle cell layer and basal 
layer, as shown in figure 1.1. The basal layer lies adjacent to the dermis and is 
composed primarily of keratinocytes, which divide and differentiate as they 
move closer to the surface. Melanocytes, which produce skin pigment melanin, 
and Merkel cells, which contribute to light touch sensation, are also resident in 
this layer (9). In the prickle cell layer, desmosomes link keratinocytes and give 
rise to the ‘prickle’ microscopic appearance the layer is named after. 
Langerhans cells are in their highest concentration in the prickle cell layer, and 
have important immunological function. By the time cells reach the granular 
layer they have flattened, lost their nuclei and their cytoplasm has a granular 
appearance. The keratin layer is the uppermost layer, composed of layers 
hexagonal corneocytes. The interior of corneocytes is primarily keratin filaments 
held together by filaggrin protein (10). Between corneocytes in the extracellular 
space are layers of lipid bilayers, which help provide the structure critical to 
epidermal function - water retention and a physical barrier pathogens, oxidative 
stress and chemical compounds. The different component layers of the 
epidermis undergo constant turnover to replace dead or damaged cells (8).  
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Figure 1.1. Histological representation of human skin layers. (a) Demonstrates the 
different layers of human skin. (b) Demonstrates in further detail the individual layers 
composing the epidermis.  
 
The dermis is the connective tissue component of the skin and provides its 
pliability, elasticity and tensile strength. It is derived from the mesoderm germ 
layer and protects the body from injury, retains water and assists in temperature 
regulation. The dermis can be divided into two layers, the thinner superficial 
layer called the papillary dermis and the thicker layer adjacent to the 
subcutaneous tissue called the reticular dermis. The subpapillary plexus marks 
the boundary and the distinction is based on the different cell density and 
connective tissue organisation (11). The dermis is home to many of the 
derivative structures of the skin including hair follicles, sebaceous glands, sweat 
glands and lymphatic vessels. It is vastly thicker than the epidermis and its size 
ranges from 0.6mm on the eyelids to 3mm on the palms and soles. In spite of 
the rich blood supply, no vessels pass through the dermal epidermal junction. 
The most abundant cell population in the dermis are fibroblasts which are 
responsible for synthesis of connective tissue matrix proteins collagen and 
elastin. The collagen provides great tensile strength and between 80-90% of 
dermal collagen is type I collagen with 8-12% being type III collagen. The 
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elastin produces elastic fibres which allow the skin to return to its normal 
configuration after distortion (12). 
The subcutaneous layer lies deep to the dermis and is not technically 
considered a skin layer. It is composed primarily of fat lobules and connective 
tissue. Cell types found in the subcutaneous layer include fibroblasts, 
adipocytes and macrophages. The deposition of fat protects internal organs and 
the skeleton from trauma, assists with the regulation of body temperature via 
insulation and acts an energy reservoir. The extensive connective tissue helps 
to connect the dermis to the underlying musculoskeletal system. Large blood 
vessels present in this layer supply the dermis with nutrients for homeostasis of 
the skin, which are able to pass into the epidermis by diffusion. Due to this high 
vascularity the tissue absorbs drugs quickly and is often used clinically as a 
route of drug administration. The thickness of this layer varies between 
considerably individuals and at different sites of the body dependent on 
nutritional status (13). 
 
1.1.2 Immune function of the skin  
A diverse immune cell population resides in both the epidermis and dermis of 
the skin. The primary cells involved in this complex system are phagocytes, 
antigen-presenting cells, mast cells and T cells. Together, despite the highly 
specialised functions of each of these cell types, they provide the host 
protection against pathogens whilst maintaining tolerance to innocuous 
substances (14).  
Macrophages occupy the highest percentage of blood cells in the skin during 
steady-state conditions. They have important roles in maintaining skin function 
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and promoting wound closure and tissue repair. Macrophages have genetically 
encoded cell surface receptors and intracellular molecules which recognise 
damage associated and pathogen associated motifs. Based on the nature of the 
stimulus macrophages are able to produce a range of cytokines and 
chemokines to attract the relevant immune cells to the site of the stimulus. At 
the late stages of wound repair, they are able to switch to a growth promoting 
and less inflammatory phenotype, aiding the resolution of inflammation by 
phagocytosing apoptotic cells (15). There is huge functional diversity of 
macrophage subsets across different organ systems. Initially macrophages in 
the skin were viewed as a rather homogenous group, acting as defence against 
invading pathogens. It is possible that the different anatomical sites within the 
skin, for example perivascular macrophages as opposed to lymphatic 
macrophages, may be more heterogeneous in function than first thought (14).  
Dendritic cells are a type of antigen-presenting cell that have the capacity to 
present antigens to naïve T cells in order to generate immunity against invading 
pathogens, in addition to tolerance to self-antigens. These functions are only 
possible in skin dendritic cells (DC) due to the capability to migrate via the 
lymphatics to local lymph nodes present in the skin, where they initiate and 
influence the adaptive immune response. Skin DCs can be divided into two 
groups based on their location: epidermal based Langerhans cells (LC) and 
dermal dendritic cells (DDC), which reside in the dermis. LCs form a network 
between keratinocytes of the epidermis and they are able to maintain their 
numbers in the absence of an inflammatory response by in-situ proliferation 
(16). DDCs are continuously renewed by bone marrow derived progenitor cells. 
In addition to their role in initiating pathogen specific immune responses, DDCs 
are also detectable within cutaneous lymph nodes during homeostatic 
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conditions, which suggest they may have a role in maintaining tolerance to 
innocuous agents (17). Further subtypes of DC’s exist (for example, 
plasmacytoid versus myeloid) but are beyond the scope of this thesis. 
Mast cells are abundant at all host-environmental interfaces and in the skin they 
are present in the dermis, close to the vascular supply. Mast cells are crucial in 
allergic responses where environmental allergens trigger mast cells to release 
histamine. This is mediated via cross-linking of immunoglobulin (Ig)E receptors 
on the mast cell surface by IgE bound allergens, promoting tissue inflammation 
(18). Beyond this response, mast cells have a role in pathogen defence, contact 
hypersensitivity responses and skin tumours (19). 
In normal skin under homeostatic conditions B cells make up a small proportion 
of cells. In contrast, the number of T cells (2.0 × 1010) is approximately twice 
that of the T cell population in the peripheral circulation (1.1 × 1010) (20, 21). B 
cells function in the adaptive immune system and are responsible for the 
production of antibodies by differentiating into plasma cells, as shown in figure 
1.2. B cells have important roles in both maintaining skin homeostasis and 
disease, with key roles in the cutaneous tumour microenvironment in 
melanoma. T cells also have a role in humoral immunity and are activated by 
antigen presenting cells. The migration of activated T cells into the skin is 
guided by cutaneous lymphocyte antigen. Regulatory T cells assist in reducing 
inflammation and maintaining self-tolerance through secretion of IL-10 and 
transforming growth factor . These have been shown to have a role in the 
pathogenesis of psoriasis, in addition to other autoimmune skin diseases. The 
majority population of T cell subtypes varies with location, with a higher 
proportion of CD8+ T cells in the epidermis and higher number of CD4+ T cells 
in the dermis (21).  
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Figure 1.2. The role and activation of B cells. B cells recognise free antigen in the 
serum using a B cell receptor.  The B cell then displays the antigen bound to MHC-II 
complex which attracts a helper T cell. CD40 ligand on the T cell acts as a co-
stimulatory factor by binding to CD40 on the B cell. In addition the helper T cell 
releases cytokines which helps the B cell multiply and mature into plasma cells which 
produce antibodies. Adapted from 
http://classes.midlandstech.edu/carterp/courses/bio225/chap17/lecture3.htm 
 
1.2 Overview of psoriasis  
Psoriasis is a chronic, autoimmune condition resulting in characteristic skin 
lesions (22, 23). The disease commonly manifests as erythematous, well 
demarcated plaques covered with silvery scales interspersed among areas of 
unaffected skin. Chronic plaque psoriasis accounts for 85% of psoriasis cases. 
The typical distribution of lesions is symmetrical on the extensor surfaces of the 
knees and elbows, lumbosacral region and scalp (24), as shown in figure 1.3. 
The scalp is the most frequently affected area and associated with poor quality 
of life and extensive pruritus (25, 26).  
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Figure 1.3. Clinical map of psoriasis lesions. Highlighted regions are the most 
frequent areas for chronic plaque psoriasis to manifest.  
 
The exact causative mechanism of psoriasis is not fully understood, however 
studies have shown both strong genetic and environmental factors have key 
roles in the pathogenesis. Smoking (27) and obesity (28) have been associated 
with higher risk of psoriasis development. Psoriasis has a prevalence of 
between 0-11.8% worldwide (29). Higher incidence rates have been reported at 
higher latitudes and also in Caucasian ethnic groups relative to other 
populations (30).  
In addition to chronic plaque, other forms of psoriasis include guttate, 
erythrodermic, inverse and pustular. Guttate psoriasis presents in younger 
individuals with sudden dissemination of erythematous papules covering the 
trunk and extremities. It is typically preceded by a streptococcal respiratory 
infection and has strong associations with human leukocyte antigen (HLA)-Cw6 
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allele. The clinical course shows more rapid involution and longer remission 
compared with other psoriatic subtypes (31, 32). Inverse psoriasis is a rare 
subtype difficult to diagnose and treat due its area of distribution in skin folds. It 
should be considered a diagnosis in any chronic inflammatory skin process 
affecting the skin folds which is unresponsive to fungal treatment (33, 34). The 
least common but potentially most harmful form is erythrodermic psoriasis 
accounting for up to 1.5% of psoriasis cases. This form can develop gradually 
or acutely from any pre-existing form of psoriasis and can affect up to 100% of 
total body skin, leading the patient susceptible to fluid loss and infection. 
Individual patients can exhibit different variants of psoriasis listed above at 
different points in time (35).  
 
1.2.1 Clinical symptoms of psoriasis  
Psoriasis can first present clinically in infancy, childhood or in adult years. 
Clinical presentation in children may differ from adults, with more frequent 
involvement of the face in children. Spontaneous remissions of varying length 
have been reported in 32% of childhood-onset psoriasis cases (36, 37). 
Psoriasis can improve or worsen in pregnancy. A study by Murase et al (38), 
involving 47 pregnant psoriasis patients showed 55% had improved 
symptomatic relief during their pregnancy, 21% saw no effect with pregnancy 
and 23% found their disease was exacerbated. Disease improvement is thought 
to be attributable to increasing oestrogen levels in pregnancy. Oestrogen 
inhibits the secretion of cytokines which drive the inflammatory processes in 
psoriasis (39, 40).   
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The lifetime incidence of nail disease in psoriasis is estimated between 80-90% 
and isolated nail disease without skin symptom manifestation accounts for 
fewer than 5% of cases of psoriasis (41). A strong correlation has been shown 
in those patients with nail involvement and those with concurrent psoriatic 
arthritis (42). Clinically nail disease in psoriasis is highly heterogeneous and 
depends upon the area of the nail affected, as shown in figure 1.4. Nail pitting, 
leukonychia and nail dystrophy are due to nail matrix involvement. Splinter 
haemorrhages, subungal hyperkeratosis and onycholysis result from disease of 
the nail bed (43, 44).  
Figure 1.4. The external and internal anatomy of human nails. Psoriatic nail 
disease symptoms depend on whether the nail matrix or nail bed is primarily affected. 
Adapted from http://healthfavo.com/human-nail-diagram.html 
 
The prevalence of psoriatic arthritis in psoriasis patients is variable affecting 
between 10-40% (45). This large range is attributable to the lack of definitive 
diagnostic criteria for psoriatic arthritis with most commonly employed being the 
CASPAR criteria (46). Clinically psoriatic arthritis can be divided into five 
subtypes and the clinical phenotype is highly variable but involves inflammatory 
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changes to joints, bones, ligaments and tendons (47). Disease affecting the 
joints commonly presents 10 years following the initial skin symptoms 
presentation (46, 48).   
Quality of life (QoL) is severely affected in psoriasis. The impact on QoL 
appeared more significant on younger patients diagnosed with psoriasis than 
those diagnosed in older age brackets (49). Moreover higher levels of anxiety 
and depression have been seen in family members of those with the disease, 
close to the anxiety level of the patient (50). In particular increased severity of 
pruritus, scaling and pain with psoriatic lesions is associated with lower QoL 
scores (51). Moreover, those with concomitant psoriatic arthritis report 
significantly lower QoL than patients without joint involvement (52). 
Psoriatic symptoms also result in considerable loss of productivity and 
absenteeism at work. A study by Graham et al, showed that on average those 
with moderate to severe psoriasis lost >8 hours of productivity at work per week 
due to their psoriasis symptoms (53). A separate study in the UK demonstrated 
that 45% changed employment completely, or role at their employment due to 
their psoriasis (54). 
The gold standard for monitoring improvement in psoriasis skin lesions has 
been the psoriasis severity and area index (PASI) score. The majority of clinical 
trials consider a minimum improvement of 75% reduction in psoriatic skin 
lesions (PASI 75) for an intervention to be considered successful treatment 
(55). The PASI 75 is generally considered a more useful evaluation tool than 
the physicians global assessment (56). Despite this reduction in PASI score 
does not always correlate with dermatology life quality index (DLQI) scores, 
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suggesting patient scoring systems should be considered more highly when 
choosing treatment methods (57).   
 
1.2.2 Genetics of psoriasis  
Two types of chronic plaque psoriasis have been proposed based on bimodal 
age of onset and genetic factors. Type 1 psoriasis is associated with a positive 
family history, presence of HLA-Cw6 allele and age of onset below 40 years of 
age. Type 2 psoriasis is less common and is not associated with a family history 
of disease, population frequency of the HLA-Cw6 allele and age of onset above 
40 year of age (58). 
Twin studies have shown greater concordance between monozygotic twins than 
dizygotic twin pairs and estimate heritability of psoriasis between 66-90% (59). 
Paternal anticipation has been demonstrated and also a parent-of-origin effect 
with a significantly higher percentage of probands having an affected father as 
opposed to an affected mother (60, 61). 
Epigenetic phenomena including DNA methylation, histone modifications and 
regulation by miRNAs also impacts on psoriasis pathogenesis and heritability 
(62, 63). Areas of CpG methylation differ between lesional and non-lesional skin 
in psoriasis patients. The promoter regions of p15 and p21 are hypo-methylated 
in psoriatic lesions. Moreover 30% of patients with psoriasis are shown to have 
methylation of the promoter of anti-apoptotic gene p16INK4a. These mechanisms 
help psoriatic keratinocytes avoid apoptosis and remain in a state of 
senescence (64). 
Genome wide association studies have mapped greater than 30 susceptibility 
loci, however up to 50% of genetic variance is accountable to an area on 
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chromosome 6p21.3 known as the psoriasis susceptibility locus 1 (PSORS1), 
as shown in figure 1.5. Within this area association with several genes has been 
shown with the strongest genetic linkage as seen with HLA-Cw6 allele (65, 66). 
Psoriasis patients who are HLA-Cw6 positive have earlier onset disease, more 
severe phenotype, koebnerization and higher remit rates in pregnancy 
compared to HLA-Cw6 negative patients. Presence of this disease allele has 
been used in clinical trials as a pharmacogenomic marker predicting response 
to ustekinumab and methotrexate treatment (67, 68).  
 
Figure 1.5. The MHC complex and PSORS1. Shows a map of chromosome 6 with a 
magnified area of the MHC region covering 6p21.1 - 6p21.3. HLA-C is found within 
class 1 of the HLA region. Adapted from 
http://journals.cambridge.org/fulltext_content/ERM/ERM5_07/S1462399403005957sup
002.htm 
 
1.2.3 Histology of psoriasis  
Hyperproliferation of the epidermal keratinocytes is one of the histological 
hallmarks of psoriasis. Mitotic activity increases dramatically causing a 
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reduction in the cell cycle from 13 days in healthy skin to 36 hours in psoriatic 
keratinocytes. This reduction in maturation time is accompanied by altered 
differentiation, which is reflected in parakeratosis (persistence of nuclei in the 
keratin layer) and absence of the granular layer of the epidermis. Scales are 
formed on the skin surface as the stratum corneum thickens under the tiny 
abscess which is rejected by exfoliation (69). These histological hallmarks are 
shown in figure 1.6.  
 
Figure 1.6. Comparison of healthy and psoriatic skin. Shows the different 
histological features between healthy skin and areas of skin affected by psoriasis. 
Adapted from (70).  
 
Abnormalities of the wnt signalling pathway have been identified in a large 
range of skin disorders and processes, including malignancy (71), aging (72) 
and wound healing (73). A study showed that W1F1 gene in the wnt signalling 
pathway was the most strongly downregulated gene compared with non-
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psoriatic individuals (74). Wnt5a has a role in epithelial differentiation and 
stimulates proliferation of endothelial cells, in part due to induction of IL-12, and 
has been shown to be strongly induced by STAT3. Wnt5a and its putative 
receptors are localised primarily to the basal layer of the epidermis of normal 
skin, with a few cells in the granular layer. In contrast, Wnt5a is overexpressed 
throughout the whole of the spinous layer in psoriasis. In addition, activated 
endothelial cells, dermal fibroblasts and neutrophil aggregates of the keratin 
layer are all strongly positive for Wnt5a (75).  
Pathological angiogenesis and lymphangiogenesis have been confirmed in 
psoriasis patients (76). Pro-angiogenic cytokines including vascular endothelial 
growth factor (VEGF), endothelial cell stimulating angiogenesis factor and 
tumour necrosis factor (TNF)- are released from keratinocytes of psoriasis 
patients. Four times the volume of new blood vessel formation has been 
demonstrated in psoriatic skin compared with non-psoriatic comparisons (77). 
Telocytes (TC) are dermal interstitial cells distinct from fibroblasts which are 
involved in skin remodelling and repair. TCs distribute around blood vessels and 
contribute to the composition their extracellular membrane. Reduction in TC 
number and structural changes have been shown to be associated with other 
skin conditions, including systemic sclerosis (78). The loss of perivascular TCs 
has been hypothesised to potentially trigger the pathognomonic clinical sign of 
psoriatic lesions, Auspitz’s sign (79).   
The presence of Munro’s microabscesses are highly specific of psoriasis 
lesions. These are infiltrating leukocytes which collect within small foci of the 
stratum corneum visible on histological analysis only (80, 81). Newer studies 
have implicated the matricellular protein CCN1, which promotes epidermal 
hyperplasia and inflammation (82).  
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1.3 The immune system and the role of IL-17  
1.3.1 Immunology of psoriasis  
The pro-inflammatory actions of cytokines are responsible for the epidermal 
changes seen in psoriasis and lead to a self-sustained feedback loop and 
chronification of the disease, as shown in figure 1.7. The production of 
interferon (IFN)- drives autoimmunity. The dermis is infiltrated by high 
numbers of plasmacytoid dendritic cells, which become active to produce IFN-. 
Once active, IFN- induces activation and maturation of conventional dendritic 
cells, which stimulate T cell proliferation and polarise T cells to form T helper 
(Th)1 and Th17 cells. This process bridges the gap between innate and 
adaptive immunity. Following these processes autoreactive T cells proliferate 
and migrate into the epidermis, a process which is controlled by the expression 
of alpha 1 beta 1 integrin on effector T cells. This precedes the onset of 
psoriasis and is crucial for development of hallmark epidermal changes (83, 84).  
 
Figure 1.7. The immune response in psoriasis. Following an initial stress to cells a 
complex interplay of inflammatory markers leads to hyperproliferation of keratinocytes. 
Adapted from (85).  
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There was surprise amongst clinicians and researchers when the primary 
source of IL-17 was identified as γδ T cells, distinct invading immune cells, and 
not Th17 cells as previously thought. Studies of murine psoriasis models have 
shown that approximately 80% of IL-17A, in addition to 60% of IL-22 were 
produced by γδ T cells. The remaining IL-17A and IL-22 producers were 
RORγt+CD3–ILCs, giving rise to 10% of IL-17A and 40% of IL-22. In human 
skin, dissimilar to mice skin (86), γδ T cells do not exist in the epidermis, with 
CD3+γδ TCR+ T cells accounting for 4% of human dermal leukocytes. γδ T cells 
express chemokine receptor CCR6 which provides them an opportunity to enter 
into the skin by activated keratinocytes and DCs (85). A study by Cai et al (87), 
demonstrated the significance of these cells in psoriasis by two methods. 
Analysis of confocal microscopy from human skin showed the dermis of 
psoriatic skin lesions was readily infiltrated by γδ T cells, whereas there were 
significantly fewer of this cell type in healthy patients. Moreover the function of 
these cells to produce IL-17 was assessed, with and without IL-23 stimulation. 
Even when stimulated with IL-23 minimal IL-17 was produced from control 
patient γδ T cells, whereas 15% of psoriasis patient γδ T cells produced IL-17 
upon IL-23 stimulation. Thus, both the absolute number of IL-17-secreting γδ T 
cells and percentage of γδ T cells secreting IL-17 were significantly higher 
compared to control samples. 
Genetic associations with genes important in T cell differentiation and 
polarisation have been shown in psoriasis. A key gene is RUNX3, a 
transcription factor important for CD8+ T cell development and promotion of Th1 
polarisation, and possibly polarisation of Th17 also. Moreover another 
transcription factor within the same Runt-domain containing family RUNX1, has 
been associated with psoriasis. RUNX1 is expressed in naïve CD4+ T cells and 
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is downregulated upon T cell receptor stimulation. The exact mechanism of how 
these genes contribute to psoriasis pathogenesis is uncertain, however it is 
possible that gain of function mutations in RUNX3, and loss of functions in 
RUNX1 may be responsible (88). Cytokines derived from Th2 cells have not 
been shown to play a role in psoriasis pathogenesis and are not increased in 
psoriatic lesions. Nevertheless, epigenetic changes including DNA methylation 
and chromatin modification of IFNG and Foxp3 genes for Th2 cells and Th2 
regulatory cells have been demonstrated when T cells are pushed more 
towards Th1 fate. It has been proposed that fewer Th2 cell associated SNPs in 
psoriasis patient genomes may be associated with T cells being more easily 
able to differentiate into pathogenic Th1 and Th17 cells, as opposed to Th2 
variants (89).  
T cells can adopt Th1 fate via secretion of IL-12 by dendritic cells. IL-12 is 
composed of two subunits, p35 and p40. The regulation and expansion of IL-17 
producing Th17 cells is controlled by IL-23, which shares the common p40 
subunit with IL-12. Expression of both p40 and p19 are significantly increased in 
psoriasis. The key role of these cytokines has been demonstrated by the clinical 
efficacy of ustekinumab monoclonal antibody, targeting the p40 subunit (90). 
TNF- has long been associated with having a key role in psoriasis 
pathogenesis and has also been a target of biologic treatments. TNF-is 
produced from activated T cells and antigen presenting cells. Independently, 
TNF- is incapable of evoking significant response from cultured keratinocytes. 
However in combination with interleukins and other cytokines it forms strong 
synergies, amplifying responses and playing a key role in the formation of 
cytokine storms. TNF- stabilises IL-17A, which potentiates the effects of IL-
17A (91, 92).  
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The failure of psoriasis inflammation resolution and the role of negative 
regulators have been studied far less than the role of initial pro-inflammatory 
molecules. Mutations in multiple negative regulator genes, including TNIP1, 
TNFAIP3 and ZC3H12C, involved in downregulation of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) pathway are associated 
with psoriasis. TNIP1 and TNFAIP3 interact with each other to inhibit NF-κB 
signalling by preventing NEMO poly-ubiquitination with subsequent degradation 
of the NF-κB inhibitor, IκB (93). ZC3H12C supresses NF-κB signalling and pro-
inflammatory gene expression in endothelial cells. Loss of function psoriasis 
associated variants in ZC3H12C gene have been associated with increased 
dermal and epidermal inflammatory molecules through overactive NF-κB 
signalling. Given ZC3H12C inhibits vascular inflammation it has been 
hypothesised this could be a contributing factors towards cardiovascular 
comorbidities in psoriasis patients (94). One gene with highly penetrant 
mutations leading to psoriasis is IL36RN, which encodes for anti-inflammatory 
protein IL-36RA, a natural antagonist for IL-1F9. Mutations in IL36RN lead to 
unopposed effects of the inflammatory cytokine IL-1F9 where NF-κB regulated 
cytokines are highly increased (95). 
 
1.3.2 The role of IL-17 in psoriasis  
IL-17A is a pro-inflammatory cytokine and part of a six-member interleukin 
family including IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, and five receptors 
(IL-17RA-RE), as shown in figure 1.8. This family of cytokines are unique in 
bearing minimal resemblance to other mammalian proteins. Despite structural 
similarity these six members have different roles in adaptive and innate immune 
system responses. Of these members the role of IL-17A is the best understood 
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and researched (96). IL-17A exists as a homodimer or a heterodimer with IL-
17F. IL-17A, IL-17F and 17A/F heterodimer have their effect via binding to a 
receptor with IL-17RA and IL-17RC subunits (97).  
 
Figure 1.8. IL-17 molecules and IL-17 receptors. Adapted from (98). 
 
From this point in the thesis IL-17A will be referred to IL-17. A major source of 
IL-17 are Th17 cells which are distinct from Th1 and Th2 cells (99). When IL-17 
was first identified in 1993 helper T cells were categorised into Th1 and Th2 
cells dependent on the cytokines they produced. IL-17 challenged this prior 
binary classification as the amino acid sequence differed from other cytokines 
previously described, and the receptor structure was not the same as that of 
other cytokine receptor families. Subsequent research led to the discovery of 
Th17 as a separate CD4+ T cell population responsible for production of IL-17 
(100). The main source of IL-17 are γδ T cells, as discussed in detail above in 
section 1.3.1. Other sources of IL-17 include mast cells, neutrophils, fibroblasts 
and natural killer cells. Studies have demonstrated the predominant cell type in 
psoriatic lesions staining positive for IL-17 are mast cells and neutrophils, with a 
higher density of these cells than IL-17 associated T cells (101). 
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Increased levels of both IL-17 and Th17 cells have been identified in the skin 
and peripheral circulation of psoriasis patients, and correlate with disease 
severity (102). One study showed that patients with PASI scores of 10 or 
higher, suggestive of moderate to severe disease, had serum IL-17A levels 
three times greater than those with PASI scores of fewer than 10. In addition, 
IL-17A mRNA expression was elevated in lesional skin compared to healthy 
skin (103). IL-17 decreases expression of cell adhesion factors resulting in 
disruption of the skin barrier, increases expression of keratin 17, reduces 
expression of filaggrin and contributes to epidermal hyperproliferation, seen 
clinically as the production of scales on the skin surface (104). IL-17A 
stimulates the innate immune system by increasing the expression of 
antimicrobial peptides, primarily members of the -defensin and S100A families 
(105). On its own, IL-17 has been shown to have only a modest effect on 
inflammation however it acts in synergy when combined with other cytokines, 
particularly TNF- and IL-1 (106). There is local production of Th17 cytokines 
within plaques which contribute to increased CCL20 production. This is key for 
migration of Th17 cells and dendritic cells into the psoriatic skin and helps 
maintain the inflammatory process (107). By stimulating fibroblast to produce 
VEGF IL-17 may promote angiogenesis in psoriasis, by the same process it 
does for many malignancies (108). 
 
1.3.3 The role of IL-17 in other autoimmune diseases  
IL-17 has a role in many different cellular process and diseases due to the 
variety of cell types it has an effect on, as shown in figure 1.9. IL-17 has a key 
role in rheumatoid arthritis (RA) pathogenesis through the production of other 
pro-inflammatory cytokines, including IL-6, IL-8, PGE2, and G-CSF, and 
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increasing osteoclastogenesis through activation of the RANKL pathway. The 
level of precursor γδ T cells in the synovium of RA patients is higher compared 
to healthy controls. Similar to psoriasis, there is also elevated CCL20 levels, 
which act as chemoattractant for Th17 cells (100). Response to IL-17 targeting 
therapies has been variable, with both secukinumab and ixekizumab showing 
clinical benefit with improved American College of Rheumatology (ACR)20 
responses in patients unresponsive to disease-modifying antirheumatic drugs 
therapy. Phase II clinical studies for brodalumab, which targets IL-17A 
receptors, show it appears to be ineffective in RA (109). 
 
Figure 1.9. The role of IL-17 across various cells types and the end effect of 
altering these pathways. Adapted from (99).  
 
Studies have shown that IL-17A and IL-17F levels are significantly higher in 
patients with multiple sclerosis (MS) than healthy controls. The higher IL-17 
levels have been shown to be associated with pathogenesis of the disease with 
neutrophil expansion in cerebrospinal fluid and disruption of the blood-brain 
barrier. Moreover, a positive correlation has been shown between increased IL-
17F levels and the number of relapses (110). It has been hypothesised that 
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Th17 cells might enhance glutamate excitotoxicity in the disease course. 
Studies have shown the IL-17A level and the number of neutrophils decreased 
with disease duration, suggesting the role of Th17 cells in MS pathology could 
be more significant in onset of the disease compared to disease progression 
(111). IL-17A targeting therapies have proven successful at reducing severity of 
the disease but this finding may explain why they fail to provide the same 
clinical benefit in later stages of the disease (112). 
In addition to autoimmune diseases IL-17 has a role in protecting the host from 
bacterial, fungal and viral infections, in particular at mucosal sites such as the 
oral cavity and lungs. Th17 cells are enriched at mucosal surfaces, and produce 
cytokine receptors which target them to mucosal areas. IL-17 is considered to 
primarily have a larger role in protection from extracellular bacterial pathogens. 
Nevertheless, IL-17 has been shown to have a role in intracellular bacterial 
infections caused by Listeria monocytogenes, Mycobacterium tuberculosis and 
Francisella tularensis (113). The most studied fungal infection for IL-17 
involvement has been Candida albicans, where together with IL-23, it has been 
shown to have a strong protective role against oral candidiasis (114). IL-17 can 
also have a negative effect on host response, as is the case in certain viral 
infections where it can contribute to cytokine storms. In an influenza infection 
model the survival rate of IL-17RA−/− mice was higher than wild type, with these 
mice showing fewer inflammatory cytokines (115). 
 
1.4 Therapeutic development in psoriasis  
At present there is no curative therapy for psoriasis and treatment is aimed at 
symptom resolution and remission. Mild cases of psoriasis are often managed 
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with topical therapies such as emollients only (116). Moderate to severe cases 
of psoriasis are treated with a range of options from systemic therapies (117), 
including methotrexate (118, 119), and phototherapy (120).  
 
1.4.1 Biologic agents in psoriasis treatment  
Biologics are reserved for treatment resistant cases in the NHS and target 
specific molecules. Biologics for psoriasis target key inflammatory molecules 
including p40, TNF- and IL-22, as shown in figure 1.10. The cost of such 
treatments is increasing and significantly higher than non-biologic treatments. 
The annual cost of maintenance treatment with etanercept in the USA is 
$46,395 and $53,909 with ustekinumab (121). In comparison treatment with the 
first line systemic agent methotrexate is only between $794 - 1,503 per year 
(122). This is an important consideration for healthcare providers when 
considering treatment.  
 
Figure 1.10. Cytokines targeted by biologics used in psoriasis treatment. Adapted 
from (123).   
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One disadvantage at present is the restriction of biologic therapies to injectable 
routes of administration, which is unsuitable for some patients. However oral 
methods of administration are being investigated for use including tofacinitib 
and apremilast (124). Tocafinitib is a JAK1/3 inhibitor developed with intent to 
treat psoriasis. The JAK family has a role in signal transduction from cytokine 
receptors to STAT in lymphocytes (125). Apremilast is a PDE4 inhibitor which 
results in anti-inflammatory effects by modulating the release and synthesis of 
cytokines and chemokines from immune cells (126, 127).  
Three biologics which target IL-17 have recently been licenced: secukinumab, 
ixekizumab, and brodalumab, as shown in figure 1.11 (128). Secukinumab, as 
well as ixekizumab, directly bind and neutralise IL-17A, whereas brodalumab 
blocks the receptor IL-17RA. All show excellent results with regard to PASI 
scores with Phase II and Phase III clinical trials showing greater than 80% of 
patients achieving PASI 75 (129, 130). Ixekizumab has shown significant 
improvement in symptom resolution for those with scalp and nail lesions, which 
are historically resistant to treatment (131). The potential role of these IL-17 
antagonists has also been explored for treatment of psoriatic arthritis (132). 
Short term safety data has been reassuring for all three biologics however 
concern has been raised over long-term safety. Blocking of IL-17A and IL-17F 
may increase risk of infection due to their role in mucocutaneous immunity. 
However due to inherent redundancy blocking of only one cytokine is unlikely to 
lead to serious comprise of host immune system (133).  
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Figure 1.11. The precise mode of action of anti-IL-17 antibodies. Ixekizumab and 
seckunimab are direct IL-17A inhibitors, brodalumab inhibits IL-17RA. Adapted from 
(134).  
 
1.4.2 Animal models of research in psoriasis  
To assist with greater understanding of the disease and therapeutic 
development, animal models should successfully mirror human psoriasis 
phenotype, be predictive, inexpensive and reproducible. As not one model at 
present fulfils all of the criteria, different approaches exist and can be used 
relative to what outcome is being tested.  
Animal models simulating psoriasis have mostly been hindered by the lack of 
such naturally occurring complex phenotype as in human psoriasis (135). 
Humans appear to be the only species where psoriasis naturally develops. The 
most commonly studied animals for psoriasis are rodents, which suffer from the 
above problem. Moreover there are several distinct differences between mouse 
skin and human skin including thickness and architecture of the epidermis, the 
density and thickness of hair follicles and the epidermal turnover rate, as shown 
in figure 1.12 (136). Nevertheless, animal models have allowed greater 
27 
 
understanding into the innate and adaptive immune systems involvement in 
psoriasis pathogenesis (137).   
 
Figure 1.12. Histological differences between mouse and human skin. Adapted 
from (70).  
 
To generate psoriasiform phenotypes in mice several approaches have been 
used, including genetically engineered animals and immunological approaches. 
Topical imiquimod application in mouse models can produce human-like 
psoriasis models which simulate histological changes, inflammation and 
phenotypic changes similar to human disease (138). Imiquimod generates a 
potent immunomodulatory effect by stimulation of Toll like receptor (TLR) 7 on 
plasmacytoid dendritic cells (pDCs). The chemical formula for imiquimod is 
shown in figure 1.13. Through this activation production of IFN- is stimulated 
which results in broad immune system activation. Mouse studies have shown 
application of imiquimod increases the number of pDCs in the skin. Additionally 
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the imiquimod also has effect on Langerhans cells, B cells, macrophages and 
monocytes (139).  
 
Figure 1.13. The chemical formula for imiquimod. 
 
Due to the limitations of psoriasis like models in rodents, the best mouse model 
for study of the disease involves xenotransplantation of human skin onto 
immunodeficient mice. Mutations in forkhead box transcription factor N1 of nude 
mice results in defective thymus development with subsequent lack of T cells, 
and mice with Prkdcscid mutations develop severe combined immune deficiency 
(SCID) (140). Studies in these groups of mice have shown psoriatic skin retains 
its phenotype for more than 2 months following transplantation and grafted non-
lesional skin adopts psoriatic skin features in these mice. Interestingly, 
transplantation of non-lesional skin triggered the development of psoriasis in the 
formerly unaffected skin from psoriasis patients, but not in healthy donor tissue 
(141). Humanised mouse models could offer great value for studying targets 
which are only expressed in human tissues and for testing antibodies or biologic 
therapies targeted at human antigens (142). 
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The overwhelming majority of biomedical research models use rodents. 
However non-human primates (NHP) are still used due to their greater similarity 
to humans in physiology, development and neuroanatomy with respect to any 
other animal. In particular, their similar social interactions and complexities have 
made them particularly useful in studying disorders of dysfunctional social 
behaviour that could not be assessed as easily with rodent models (143).  
An Aldara-induced skin inflammation model was developed in baboons for the 
first time in 2016. Reversibility of erythema and skin thickening was 
demonstrated on cessation of Aldara application and similar to mouse models, 
the histopathological analysis of the baboon skin showed acanthosis, 
hyperkeratosis, epidermal hyperproliferation and hypergranulosis. Moreover, 
mRNA analysis of skin biopsies showed overexpression of the IL-17 pathway 
(144). This suggests such a model could be of interest for testing efficacy, as 
well as safety, of anti-IL-17 agents on NHPs in the future. 
 
1.4.3 Development of a vaccine towards psoriasis treatment  
The therapeutic use of vaccines has been demonstrated in other autoimmune 
disorders such as myasthenia gravis. Similar to treatment with antibodies, the 
use of an antigen specific vaccine could avoid the nonspecific effects of current 
immunosuppressive drugs, such as infection. The results suggest the vaccine is 
a safe, rapidly acting and effective treatment for myasthenia gravis (145). 
Autovaccination aims to induce self-specific antibodies with the assistance of a 
small number of T cells. This is preferentially B-cell targeted with VLPs. Thus 
these vaccines are designed to induce antibodies as opposed to T cells. The 
vaccine used in this thesis employs use of virus like particles (VLP) for this 
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purpose, which has two advantages. First, when arranged in repetitive 
structures antigens on the surface of VLPs can directly activate B cells. Second, 
VLPs bypass Th cell tolerance as they are not innate cells, thus they produce a 
strong B cell response without self-specific Th cell responses (146). Clinical 
studies have been undertaken where VLP-based vaccines have targeted 
angiotensin for arterial hypertension and interleukin-1 to treat type I diabetes. 
In these trials no safety issues have been raised. Moreover, these studies have 
shown the vaccines to be highly immunogenic and achieve clinical efficacy 
(147, 148). 
Many potential vaccines fail to make it beyond clinical trials. The reasons for 
this include lack of immunogenicity in human trials and the costs associated 
with proving vaccine efficacy (149). Another potential problem facing vaccine 
development for late onset disorders is the aging population. 
Immunosenescence in the elderly population makes these individuals 
increasingly susceptible to disease, and although vaccination is a protective 
factor, the failing immune system as we age makes targeting vaccines at this 
age group more difficult (150). However vaccines targeted at elderly populations 
have been successful, such as vaccination against Herpes Zoster and post-
herpetic neuralgia in elderly patients, which has shown to dramatically reduce 
morbidity from these conditions and is cost effective (151).   
IL-17 has been extensively studied as a target of biologic therapies with 
promising safety and efficacy data (146). In terms of safety this has already 
been demonstrated in patients who lack genes responsible for making IL-17A 
and those who cannot make its receptor molecule IL-17RA, in addition to those 
with naturally occurring high levels of antibody against IL-17A and IL-17F. In 
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these patients tuberculosis, fungal and microbial infections did not occur nor did 
the patients develop cancer (152, 153).  
Development of a vaccine allows for several advantages against current 
biologic treatments. Firstly, vaccine production costs could dramatically 
undercut current prices for biologic drugs offering a cheaper alternative for 
patients and healthcare providers. Secondly, vaccines promote active immunity 
whereby the body naturally produces an immune response, as shown in figure 
1.14, compared to passive immunity provided by biologic medications. This 
mechanism of generating an adaptive immune response offers long-term - 
potentially lifelong - immunity whereas biologics require regular doses to be 
administered to patients (154).  
 
Figure 1.14. The mechanism of action of vaccines. Vaccines promote active 
immunity where the body creates memory T cells which, when exposed to the antigen, 
are able to stimulate B cells to differentiate into plasma cells and produce targeted 
antibodies. Adapted from (155).  
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1.4.4 Description of the vaccine 
The complete IL-17A heterodimer, as opposed to specific domains, is used as 
the antigen. Despite increased production complexity the entire protein was 
used as studies of VLP based vaccines have shown greater efficacy using 
entire proteins rather than selected epitopes. The most likely reasons for this 
are because using the entire protein will capture not only the greatest number of 
potentially immunogenic linear epitopes but also, in difference to single 
domains, all conformational epitopes. Multiple copies of the IL-17A are 
covalently attached to the VLP using a hetero-functional chemical cross-linker 
succinimidyl-6-[(β-maleimidopropionamido) hexanoate]. The VLP is derived 
from the plant restricted cucumber mosaic virus (CMV). This is a linear single-
stranded RNA icosahedral plant virus. Both the IL-17 and VLP intermediates 
are recombinantly expressed in E. coli and purified. The vaccine is designed to 
overcome immunological self-tolerance and to elicit autoantibodies that are able 
to bind specifically to IL-17A.  
The amino acid sequence of the CMV coat protein differs from natural CMV 
sequence by way of a tetanus toxoid T cell epitope inserted at the N terminus. 
This modification is designed to improve vaccine immunogenicity in those who 
have previously been exposed to tetanus vaccination, which is close to the 
whole population in developed countries.   
 
1.5 Thesis Aim and Rationale  
Antibodies targeting IL-17A to treat psoriasis have confirmed that at present up 
to 5 years continuous inactivation of IL-17A in humans is safe. Between the 
three IL-17A targeting antibodies several thousands of years of patient safety 
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data show they do not result in systemic immuno-suppression, increase 
incidence of malignancies or other treatment associated side effects (156). 
Moreover, similar data is observed in studies of patients with inborn mutations 
in the IL-17A signalling pathway, with the main increased risk being of 
mucocutaneous limited candidiasis (157). Combined, these provide 
independent clinical evidence that long-term IL-17A inactivation is not 
associated with increased risk of severe toxicity or mortality.  
Prolonged clinical studies for the IL-17A targeting monoclonal antibodies have 
also confirmed that neutralisation of IL-17A is a highly effective treatment option 
in psoriasis patients, with superior efficacy compared to other treatment 
modalities, and achieving measurable improvement in disease control for most 
patients taking these therapies (158, 159). Their superiority is to such an extent 
that all three monoclonal antibodies (secukinumab, ixekizumab, brodalumab) 
have been licensed as first-line treatment for psoriasis in the USA, Japan and 
the European Union. 
The data generated for IL-17A neutralising monoclonal antibodies demonstrates 
a comparatively safe and highly effective treatment modality, which makes this 
highly sought after by patients and clinicians. However, the cost of placing 
patients on monoclonal antibody treatment is a major limitation to their use in 
clinical practice at present. Despite production of biosimilars for monoclonal 
antibodies and market competition reducing prices, the production process 
required to generate these complex molecules on large scales translates into 
significant per-patient cost. As such this makes it difficult for health care 
providers, including the NHS, to offer this readily to patients before much 
cheaper, but often less effective, treatment modalities.   
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The advent of IL-17A active vaccination offers the opportunity to replace the 
limitation of high costs associated with passive immunisation by monoclonal 
antibodies. In addition to the financial advantage, active vaccination could offer 
advantages including ease of dosing and avoidance of anti-drug antibodies. 
Should the vaccine demonstrate consistent effectiveness it has the potential of 
being used in treatment of other common diseases with underlying IL-17 
associated aetiology, including rheumatoid arthritis and multiple sclerosis.  
VLP based vaccine technology has been extensively studied (160), offering a 
validated platform for clinical development of an vaccine targeting IL-17A. At 
present, IL-17A is the cytokine with the most supporting evidence to validate a 
potential therapeutic auto-vaccine in psoriasis patients.  
Given the above, the current thesis explores whether IL-17A-targeted 
vaccination could provide a feasible treatment approach for psoriasis. To do so, 
a prototype of such a vaccine was characterised with respect to its 
immunogenicity, the specificity of antibodies generated, the clinical in vivo 
efficacy in a mouse model of psoriasis, and the long-term development of 
antibody titres, including reversibility and ability to re-boost titres. By 
undertaking this pre-clinical trial our aim was to understand whether this 
treatment approach had potential applicability for human psoriasis patient use in 
the future. 
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Materials and Methods  
 
2.1 Ethics statement  
All regulated procedures performed on the mice as part of this study were 
conducted by personal licence holders in concordance with The Animals 
(Scientific Procedures) Act 1986. Study design and rationale for each individual 
experiment was approved by the Welfare and Ethical Use of Animals 
Committee at the University of Dundee.  
 
2.2 Home Office Licence    
In order to carry out experiments involving animals, individuals must have a 
personal licence from the Home Office and the procedures only authorised if 
carried out as part of a project for which there is a project licence granted. The 
project licence number used for this work is 64/2950 and the personal licence 
number used is ID74393FD.  
 
2.3 Chemicals, reagents and buffers  
All general chemicals were of molecular biology grade and obtained from 
Sigma-Aldrich (Gillingham, Dorset, UK), Fisher Scientific (Loughborough, 
Leicestershire, UK), eBioscience (Altrincham, Cheshire, UK), R&D (Abingdon, 
Oxfordshire, UK), Promega (Southampton, Hampshire, UK), BioLegend 
(London, UK) unless otherwise stated.  
The IL-17 vaccine was obtained through academic collaboration with the Jenner 
institute at Oxford University.  
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2.4 Mice information   
2.4.1 Species of mice and breeding  
Wild type female C57Bl/6j mice were used across all the experiments. All mice 
were aged 6-10 weeks at the beginning the experiments, with the exception of 
the older group of mice involved in the diphtheria, pertussis and tetanus (DPT) 
pre-immunisation experiment, who were aged 7-8 months. All mice were 
purchased from a commercial breeding unit. No mice used in these experiments 
were bred in the resource unit.  
 
2.4.2 Animal husbandry  
Mice were checked everyday by members of the resource unit staff to ensure 
their health and wellbeing, and provided adequate food and water supply. Up to 
5 mice were stored in M2 cages. Environmental enrichment was provided in 
each cage and changed over time to provide a suitable living environment for 
the mice.  
 
2.4.3 Mouse identification  
All mice in the experiments underwent ear tagging so that they could be easily 
identified for hematoxylin and eosin (H&E) analysis and ear thickness 
measurements. The designation for ear tagging is shown below in figure 2.1.   
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Figure 2.1. Mouse identification scheme. Shows the ear tagging system used for 
mouse identification as part of this study.   
 
2.5 Procedures  
2.5.1 Blood Sampling  
The procedure used for tail vein blood sampling was as follows. The cages 
were placed on heat pads for 15 minutes prior to tail vein blood sampling to 
allow adequate dilation of the tail veins. A small incision over the vein was made 
and a capillary tube used to collect the tail vein blood. No restraint device was 
used during the procedure. Up to 200l of blood was collected at each 
occasion. 
Cardiac puncture was used in place of tail vein blood sampling when blood 
samples were to be acquired at the time of scheduling. The procedure used for 
cardiac puncture was as follows. The mice were placed in dorsal recumbency 
and the xiphisternum palpated. The 21G needle was inserted inferior to the 
xiphisternum and gentle suction applied to the syringe. The needle was 
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advanced until blood was aspirated. Up to 200l of blood was collected at each 
occasion. 
Once blood samples were acquired these were inverted 5 times each and then 
centrifuged at 10,000rpm for 90 seconds. Serum, ranging from 30 to 120l, from 
each sample was aliquoted into safe-lock tubes. The serum was stored at           
-800C.   
 
2.5.2 Injections  
Subcutaneous injections were carried out with the mouse restrained with the 
scruff grasped between the thumb and forefinger and the tail gripped between 
the third and fourth finger.  
 
2.5.3 Application of imiquimod  
Dorsal skin was shaved prior to application of imiquimod cream. The 
mechanism by which imiquimod induces a psoriasis like reaction is discussed in 
the results section. Approximately 50mg of Aldara cream (one sachet) was 
applied to the dorsal skin and ear for each individual mouse at every 
application.  
 
2.5.4 Scheduling  
All mice in this study were humanely killed by dislocation of the neck or inert 
gas asphyxiation in accordance with Schedule 1 methods under The Animals 
(Scientific Procedures) Act 1986. Inert gas asphyxiation was used where blood 
samples were to be acquired at the time of scheduling. Where blood samples 
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were not required at time of scheduling dislocation of the neck was used. The 
death of each animal was confirmed before appropriate disposal.  
 
2.6 Monitoring of mice  
2.6.1 Ear thickness and body weight measurements  
Ear thickness measurements and body weight measurements were recorded at 
different time intervals during the experiments using a micrometre and a scale 
respectively. Daily checks of the health of the mice and provision of food and 
water were made by staff in the animal resource unit.  
 
2.6.2 Clinical photographs  
For taking of photographs to document the dorsal skin phenotype after 
imiquimod application mice had their dorsal skin shaved to remove overlying 
hair obscuring the underlying view. The mice were photographed individually at 
the time of scheduling, against a plain background with the cage card for the 
corresponding cage photographed to help identify the mice in the experiment.  
 
2.7 H&E based histology  
2.7.1 Tissue acquisition  
Ear samples and dorsal skin samples were taken, roughly 2cm by 2cm, and 
placed in formalin pots. Dorsal skin was shaved prior to sample analysis. 
Samples were taken from central areas with the least overlying hair, as shown 
in figure 2.2.   
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Figure 2.2. Areas of tissue acquisition for histology analysis. Outlined in yellow the 
area of dorsal skin removed for H&E analysis, as opposed to the shaved area with 
more overlying hair posterior to this outlined area.  
 
Tissue fixation, embedding and staining were carried out by staff at the Tayside 
Tissue Bank Dundee. The procedures involved are described below.  
 
2.7.2 Tissue fixation  
The tissue was fixed in neutral buffered 10% formalin, which prevents the 
conversion of formaldehyde to formic acid. 2ml of formalin was used per 100mg 
of tissue. Tissues were fixed for a minimum of 48 hours at room temperature. 
Tissue was then dehydrated through a series of graded ethanol immersions to 
displace water. Once fixed, the tissue was processed as follows on a Leica 
Peloris tissue processor as per the standard NHS Tayside Pathology laboratory 
8 hour protocol: formalin x2, 95% ethanol x4, 99% ethanol x4, xylene (first 
cleaning agent), 99% ethanol (second clearing agent), first paraffin wax and 
second paraffin wax.  
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2.7.3 Embedding process  
Wax was melted by placing tissue cassettes in a 580C paraffin bath for 15 
minutes. Mould was selected that left 2mm margins of paraffin wax around the 
tissue.  Molten paraffin was dispensed in mould and warm forceps were used to 
transfer tissue into the mould, placing the cut side down. The mould was 
transferred to a cold plate and gently the tissue was pressed flat. With the tissue 
in the desired orientation the labelled tissue cassette was added on top of the 
mould as a backing. After 30 minutes the wax was cooled and hardened, and 
the paraffin block was then popped out of the mould. Tissues were then 
sectioned using a Leica microtome to 4µm thickness. The sections were dried in 
an oven at 370C.  The tissue and paraffin attached to the cassette formed a 
block, which were stored at room temperature. 
 
2.7.4 Staining procedure  
Haematoxylin and Eosin staining was performed using Leica Autostainer XL. 
The procedure was as follows: tissue was placed in an oven at 600C for 15 
minutes. Sections were deparaffinised by using 3 changes of xylene for 30 
seconds each. These sections were re-hydrated in 2 changes of absolute 
alcohol for 30 seconds each. This was followed by 99% alcohol for 2 minutes 
and 95% alcohol for 2 minutes and washed in water for 30 seconds. Sections 
were stained in Harris haematoxylin solution for 4 minutes and washed in 
running tap water for 1 minute. Sections were differentiated in 0.1% acid alcohol 
for 1 minute and then washed in water for 1 minute. Bluing in saturated lithium 
carbonate solution for 1 minute followed this. Eosin solution was used to 
counterstain for 20 seconds and washed in tap water for 30 seconds. These 
were rinsed in 95% alcohol for 30 seconds two times and rinsed in 99% alcohol 
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for 30 seconds two times before final rinsing with Isopropyl alcohol for 30 
seconds. Sections were cleared in 3 changes of xylene for 30 seconds each. 
Sections were coverslipped by Leica Coverslipper CV5030 using DPX 
mountant. 
 
2.8 ELISA experiments  
There are many different types of enzyme-linked immunosorbent assay (ELISA) 
tests, as shown in figure 2.3. The experiments carried out as part of this thesis 
used sandwich ELISAs involving secondary antibody conjugates.  
 
Figure 2.3. The different types of ELISA experiments.  Adapted from 
http://www.abnova.com/support/resources.asp?switchfunctionid=%7B70196CA1-59B1-
40D0-8394-19F533EB108F%7D 
 
First Nunc-Immuno 96 clear polystyrene MicroWell solid plates were coated as 
follows. Recombinant murine IL-17 was diluted to a concentration of 2g/ml in 
phosphate-buffered saline (PBS) and vortexed to allow adequate mixing. 100l 
of this mixture was added to each well of the plate using a multi-channel pipette. 
The plate was covered with parafilm and stored at 40C for up to 72 hours.  
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Wash buffer was made using PBS with 0.05% Tween20 and blocking buffer 
made from the washing buffer composed of 2% bovine serum albumin (BSA) in 
PBS with 0.05% Tween20. The plate was removed from the fridge, the liquid 
expelled and the plates washed 3 times with 200l wash buffer per well. 250l 
blocking buffer was added to each well and the plates left for 150 minutes.  
Serum was serial diluted in wash buffer on 96-well plates to the following 
concentrations: 1:30, 1:100, 1:300, 1:1000, 1:3,000, 1:10,000 and 1:100,000. 
Control serum, taken before any antibody or vaccination injections, was used in 
each experiment and diluted to a concentration of 1:100. This high 
concentration relative to the test samples was used to allow for enough control 
serum to be used for all the experiments. Liquid was discarded from the blocked 
plate and the plate was washed 3 times as above. 50l of diluted serum was 
transferred onto the coated plate and with each sample a duplicate of each 
sample used. Empty wells were filled with 50l sterile water for standardisation 
purposes and the plate incubated for 90 minutes on the shaker.  
Detection antibody was made using Anti-mouse IgG labelled to alkaline 
phosphatase, diluted in blocking buffer to a concentration of 1:5000. Liquid was 
discarded from the blocked plate and the plate was washed 3 times as above. 
100l of detection antibody was added to each well and the plates covered with 
parafilm and left to incubate on the shaker for 45 minutes. Liquid was discarded 
from the blocked plate and the plate was washed 3 times as above. 50l of 
alkaline phosphatase yellow (pNPP) liquid substrate was added to each well 
and the wells incubated on the shaker for 20 minutes. 5l of stop solution (3M 
NaOH) were added to each well and the plate read in the SpectraMaxM3 
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spectrophotometer at 405 nanometres. This whole process is summarised in 
figure 2.4.  
 
Figure 2.4. The sequence of events in the ELISA experiments. The top half shows 
positive results whereas the bottom half a negative result. Adapted from 
https://cellularphysiology.wikispaces.com/Enzymelinked+immunosorbent+assay+(ELIS
A) 
 
SoftMax Pro6.3 software was used to read the plates. Absorbance instruments 
with endpoint settings of 405nm wavelength were used. ELISA data were 
analysed using a 3-parameter logistic fit according to standard sigmoid curve 
equation, Y = MAX/(1+(x/EC50)^(SLOPE)) where the minimum was set to zero 
after subtracting the sterile water optical densities from test values. Curve fitting 
was done using the ‘solver’ add-in using the GRC-nonlinear fitting algorithm. 
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2.9 Protocols for individual vaccine experiments  
2.9.1 Immunogenicity of the immune response generated by the vaccine 
procedure  
Mice were subjected to tail vein blood sampling, as described above in section 
2.5.1. Tail vein blood (up to 200l) was ascertained prior to the first vaccination 
and two weeks post final vaccination. Vaccination was carried out on day 1, day 
15 and day 28. 
The mice were divided into groups as documented in table 2.1 
 
Table 2.1. Group allocation for immunogenicity experiment.  
 Number of Mice Vaccination dose 
(micrograms) 
Group 1 4 1.25 
Group 2 4 2.5 
Group 3 4 5.0 
Group 4 5 0.5 
 
2.9.2 Assessment of vaccine efficacy procedure  
The first phase of the experiment involved vaccination of the mice in group 1 
only as follows. 5 female wild type C57Bl/6j mice, aged 6-8 weeks were chosen. 
Tail vein blood (up to 200l) was ascertained on day 1, day 15 and day 29 of 
phase I. Mice were injected subcutaneously with a single dose of 50l IL-17 
vaccine on day 1 of phase I.  
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The second phase of the experiment involved IL-17 dosing as follows. The mice 
were divided into groups as documented in table 2.2 
 
Table 2.2. Group allocation for efficacy experiment.  
 Number of 
mice 
Imiquimod 
Application 
Therapy 
Group 1 5 Yes Vaccinated in phase 1 
Group 2 5 Yes None (positive control) 
Group 3 5 Yes Antibody injection 
Group 4 3 No None (negative control) 
 
The below procedures were performed as part of the experiment.  
Cream treatment: Aldara cream was applied to the one ear of all animals daily 
and to shaved dorsal skin (area approximately 2 x 2 cm) for up to 8 days of 
phase II to groups 1-3 mice only. 
Antibody injection: 100g of anti-IL-17 was injected in 100l volume 
subcutaneously on day 1 and day 3 of phase II into group 3 mice only. 
The mice ear thickness and body weight were monitored throughout. Ear 
thickness was recorded using a micrometer on day 1 and day 4 of phase II and 
the day of scheduling. Body weight was determined on day 1 of phase II and at 
scheduling. 
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2.9.3 Long-term kinetics experimental procedure  
Three groups of C57Bl/6j females (n = 4 per group), aged 8-10 weeks at 
baseline. All groups were subjected to 50l of vaccine subcutaneously on day 1, 
day 15 and day 29.  
Tail vein blood (up to 200l) was ascertained on the days of vaccination, 2 
weeks after the last injection, then once monthly until scheduling of mice at 
week 58.  
The mice were divided into groups as documented in table 2.3. The mice used 
for this experiment were used to evaluate several questions in line with the 3Rs 
of animal research - replacement, reduction and refinement. Therefore table 2.3 
also documents the questions addressed by altering procedures between these 
three groups.  
  
48 
 
Table 2.3. Group allocation for long-term kinetics experiment.  
 Number 
of Mice 
Procedure Question 
addressed 
Group 
1 
4 1) Induced psoriasis flare (by 
imiquimod cream applied once daily for 
7 days to shaved dorsal skin 3 months 
from baseline).  
2) Repeated complete vaccine scheme 
as at baseline (3 injections) to be 
administered once antibody titre has 
decreased by >50% from maximal 
(group average). 
1) Is there 
‘endogenous 
boosting’ of titre? 
2) Does repeat 
vaccination lead 
to overall higher 
titres? 
Group 
2 
4 Single injections of vaccine 
administered at 3, 6, 9 months from 
baseline 
Does repeated 
boosting prolong 
overall titre? 
Group 
3 
4 Repeated complete vaccine scheme 
as at baseline (3 injections) to be 
administered once antibody titre has 
decreased by >50% from maximal 
(group average) or at nine months from 
baseline 
How long does 
titre after single 
vaccination 
induction last? Is 
it higher after 
second boosting? 
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2.9.4 Enhancing vaccine responses by pre-DPT injection procedure  
C57Bl/6j female mice, of ages specified below (n = 5 per group) were used. 
DPT vaccine was administered as single 50l subcutaneous dose. IL-17 
vaccine was administered in all groups as triple-induction (subcutaneous 
injections of 10l of vaccine on day 1, day 15 and day 29). The first dose of IL-
17 vaccine was given 4 weeks after DPT vaccination. 
The mice were divided into groups as documented in table 2.4 
 
Table 2.4. Group allocation for DPT pre-vaccine assessment experiment.  
 Number of 
Mice 
DPT pre-vaccine Mouse age 
Group 1 5 Yes 8 - 10 weeks 
Group 2 5 No 8 - 10 weeks 
Group 3 5 Yes 7 - 8 months 
Group 4 5 No 7 - 8 months 
 
Tail vein blood (up to 200l) was ascertained at baseline, at each vaccination 
time point, 2 weeks after final IL-17 vaccination, and every 4 weeks thereafter 
up to 26 weeks when the mice were scheduled.  
 
2.9.5 Enhancing vaccine responses by blocking IL-22 procedure  
The first phase of the experiment involved vaccination of the mice in group 1 
only as follows. 5 female wild type C57B/6j mice, aged 6-8 weeks were chosen. 
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Mice were injected subcutaneously with 50l of IL-17 vaccine on day 1, day 15 
and day 29 of phase 1.  
Tail vein blood (up to 200l) was ascertained prior to vaccination, on day 29 and 
at the beginning of dosing (phase II) on day 43.  
The second phase of the experiment involved IL-17 dosing as follows. The mice 
were divided into groups as documented in table 2.5 
 
Table 2.5. Group allocation for blocking of IL-22 experiment.  
 Number of 
Mice 
Imiquimod 
Application 
Therapy 
Group 1 5 Yes Vaccinated in phase 1 
Group 2 5 Yes None (positive control) 
Group 3 5 Yes Antibody injection 
Group 4 3 No None (negative control) 
 
The below procedures were performed as part of the experiment.  
Cream treatment: Aldara cream was be applied to one ear of all animals daily 
and to shaved dorsal skin (area approximately 2 x 2 cm) for 11 days of phase II 
to groups 1-3 mice only 
IL-22 antibody injection: 100g of anti-IL-22 antibody was injected as 100l 
subcutaneously on day 1 and day 3 of phase II into groups 1-3 mice only. 
Antibody injection: 100g of anti-IL17 was injected in 100l volume 
subcutaneously on day 1 of phase II into group 3 only. 
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The mice ear thickness and body weight were monitored throughout. Ear 
thickness was recorded using a micrometer on day 1, day 4, day 8 and the day 
of scheduling. Body weight was determined on day 1 and at scheduling. 
 
2.9.6 Enhancing vaccine responses by formulation with aluminum gel procedure  
The first phase of the experiment involved vaccination of the mice in groups 1 
and 2 only as follows.10 mice (n = 5 per group) were vaccinated on day 1, day 
15, and day 28 of phase I with standard anti-IL-17 vaccine (group 1), or anti-IL-
17 vaccine in alum-hydrogel (group 2). Vaccine dose was 25g of vaccine in 
each group, the alum-hydrogel vaccine was composed of 25g of vaccine and 
25g of alum-hydrogel.  
Tail vein blood (up to 200l) was ascertained at each vaccination, 2 weeks after 
the final vaccination and 4 weeks after the final vaccination.  
The second phase of the experiment involved IL-17 dosing as follows. The mice 
were divided into groups as documented in table 2.6 
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Table 2.6. Group allocation for formulation of IL-17 vaccine experiment. 
 Number of 
Mice 
Imiquimod 
Application 
Therapy 
Group 1 5 Yes Standard vaccine 
Group 2 5 Yes Vaccine in aluminum 
Group 3 5 Yes Antibody injection 
Group 4 5 Yes None (positive control) 
Group 5 3 No None (negative control) 
 
The below procedures were performed as part of the experiment.  
Cream treatment: Aldara cream was be applied to one ear of all animals daily 
and to shaved dorsal skin (area approximately 2 x 2 cm) for 11 days of phase II 
to groups 1-4 mice only.  
Antibody injection: 100g of anti-IL17 was injected in 100l volume 
subcutaneously on day 1 and day 3 of phase II into group 3 mice only. 
Groups 4 and 5 received no treatment in phase I. Group 4 received Aldara 
cream as above to induce inflammatory disease with no modifier, to act as 
positive controls for treatment groups, whilst group 5 did not have skin disease 
induced to act as the negative control. Groups 3 to 5 did not have blood 
ascertained.  
The mice ear thickness and body weight were monitored throughout. Ear 
thickness was recorded using a micrometer on day 1 and day 5 of phase II and 
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the day of scheduling. Body weight was determined on day 1 of phase II and at 
scheduling. 
 
2.9.7 Specificity of the immune response generated by the vaccine procedure  
Residual tail vein blood samples known to be highly immunogenic for IL-17A 
were taken from week 10 mice of the long-term kinetics study. ELISA plates 
were coated for IL-17A and IL-17F. The same blood samples were tested for 
both IL-17A and IL-17F and the ELISA was run for both at the same time to 
minimise variables.  
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Results  
 
A series of experiments were performed in mice as proof of concept for the 
primary pharmacodynamic action of the vaccine, that is, the production of 
antibodies and the ability to block a psoriasis-like disease model in vivo. In 
addition, in order to obtain informative data on the principle pharmacokinetic 
parameter, the duration of antibody response was also assessed. The results of 
these experiments are presented below.  
 
3.1 Immunogenicity of the immune response generated by the vaccine  
Mice were immunised with increasing doses of the murine IL-17 vaccine 0.5, 
1.25, 2.5 and 5.0 micrograms respectively, via a regimen composed of three 
subcutaneous injections given two weeks apart. Serum was ascertained from 
the mice two weeks following the last injection and antibody titres determined by 
ELISA. As shown in figure 3.1, a dose of 2.5μg of VLP-coupled IL-17A vaccine 
substance elicited uniform anti-IL-17A Ig titres in excess of 1:1000 in all 
vaccinated mice. Moreover, figure 3.1 shows a vaccine dose as low as 0.5 
micrograms still produces detectable titre with an average in excess of 1:1000 
in this group.  
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Figure 3.1. Immunogenicity of the immune response generated by vaccination 
with an anti-IL-17A vaccine in mice. Figure shows the anti-IL-17A Ig titres 
determined based on half-maximal OD405 values with altered vaccine dose. Horizontal 
black lines represent the average in each group. Pre-immunised mice yielded anti-IL-
17A Ig titre levels between 0 and 50, which was comparable to sterile water.  
 
3.2 Specificity of the immune response generated by the vaccine  
Blood samples with high anti-IL-17A titre levels were used to see what effect 
this had on IL-17A’s most closely related isoform, IL-17F. Figure 3.2 shows the 
antibody response generated was highly specific, as no significant antibodies 
reactive to IL-17F were detectable across all dilutions.   
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Figure 3.2. Specificity of the immune response generated by vaccination with an 
anti-IL-17A vaccine in mice. Demonstrates ELISA assays of n = 4 mice were 
performed with plating either recombinant murine IL-17A (black circles) or IL-17F (open 
circles). Data shown represent average and standard deviation.  
 
3.3 Efficacy in an in vivo model of IL-17 mediated skin disease  
As described in the methods section, imiquimod cream was used to induce 
psoriasis like reaction in vivo. Multiple models for simulating psoriasis have 
been proposed and utilised in mice. While it is widely recognised that no single 
mouse model equates the human disease, the most widely employed in vivo 
model for psoriasis, is the topical imiquimod challenge model. This model is 
based on applying the Toll-like-receptor 7/8 agonist imiquimod as cream to the 
shaved skin (138, 139). Application of imiquimod cream elicits a psoriasis-like 
skin disease, which has been extensively characterised and, importantly, 
involves IL-17 signalling. With regard to the IL-17 vaccine, the main point to 
consider was whether the vaccine would afford a similar degree of protection as 
monoclonal antibodies targeting IL-17A. Since these monoclonal antibodies 
57 
 
have already shown efficacy in treating human psoriasis demonstration that the 
vaccine has comparable effects in an IL17-mediated model of psoriasis would 
provide sufficient evidence to support further development. Therefore, we 
conducted a head-to-head comparison with an anti-IL-17A monoclonal 
antibody, which is known to be highly effective for the treatment of psoriasis. As 
a comparator to the vaccine the most extensively used available monoclonal 
antibodies known to neutralise IL-17A in vivo in mice were used (MAB421, 
R&D, ND50 ≈ 10μg/ml). 
 
As shown in figure 3.3, the increase observed in ear thickness caused by 
application of imiquimod was reduced in mice vaccinated against IL-17A to the 
same extent as in those treated with IL-17A targeting monoclonal antibody.  
 
Figure 3.3. Reduction of increase in ear thickness caused by topical treatment 
with imiquimod in mice receiving anti-IL-17A or in mice pre-vaccinated against 
IL-17A (n = 5 per group). * p < 0.05 of imiquimod-only versus vaccinated mice in a two-
sided unpaired T-test. Data shown represent averages and standard deviation.  
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The epidermal thickness of the dorsal skin treated with imiquimod also showed 
a statistically significant reduction (p = 0.0007) achieving the same result as the 
monoclonal antibody, as shown in figure 3.4. 
 
Figure 3.4. H&E stained dorsal skin taken from imiquimod-treated mice, and mice 
receiving concurrent anti-IL-17A treatment or vaccinated against IL-17A, as 
indicated. Left: representative samples, shown at 100x magnification. * denotes a sub 
corneal deposit of neutrophils (a so-called Munro-type micro-abscess), typical of 
psoriasis, which was occasionally seen in imiquimod-treated mice, but not in vaccine- 
or antibody treated mice. Right: quantification of n = 5 mice per treatment group. ** p< 
0.01 in a two-sided T-test. 
 
Analogous results were also demonstrated in epidermal thickness of the ears 
from the same mice with a highly significant reduction (p = 0.0004), as shown in 
figure 3.5. Again, these results were in line with the IL-17 targeting monoclonal 
antibody.  
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Figure 3.5. H&E stained ear taken from imiquimod-treated mice, and mice 
receiving concurrent anti-IL-17A treatment or vaccinated against IL-17A, as 
indicated. Left: representative samples, shown at 100x magnification. Right: 
quantification of n = 5 mice per treatment group. ** p< 0.01 in a two-sided T-test. 
 
3.4 Long-term kinetics of the antibody response  
An important safety consideration of auto-vaccines is reversibility of the induced 
anti-vaccine immune response, in addition to long-term kinetics with repeat 
challenge. Another important safety aspect to consider is the potential of 
endogenous boosting of the anti-IL-17A immune response in the context of 
active psoriasis-like disease. To gain insight into these vaccine-relevant factors, 
mice received a baseline vaccination regime consisting of three inoculations 
given two weeks apart. Thereafter, as shown in figure 3.6, one group of mice 
(dark shaded) received no further treatment, while another (light shaded) was 
subjected to a simulated psoriasis flare induced by seven days application of 
imiquimod to shaved dorsal skin (grey box). Application of imiquimod did not 
trigger endogenous boosting of anti-IL-17A titres.  
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Figure 3.6. Response of anti-IL-17A titres in mice receiving endogenous IL-17 
boosting. Light shaded group (n = 4) were subjected to imiquimod challenge at 6 
weeks as shown by the grey box. Dark shaded group (n = 4) did not receive any further 
treatment after initial triple-booster.  
 
Next, the long-term titre development after vaccination and the effect of re-
boosting were characterised. As the group receiving the endogenous boost 
(figure 3.6) did not respond differently to the group without the endogenous 
boost vaccinated at the same time intervals, these two were subsequently 
analysed as a single group, as shown in figure 3.7. This group received one 
single triple-shot booster regimen at 24 weeks (black arrows). An additional 
group of mice, the second group (white symbols) received single vaccine 
booster injections every 12 weeks as above up till 36 weeks (white arrows). The 
resulting IL-17-specific IgG titres show that, as expected, the vaccination effects 
were reversible. Titre reversal was noted by 14 weeks in the absence of any 
boosting (black symbols). A single triple-injection boost completely restored 
antibody titres but did not lead to “super-boosting” (that is, >5 x higher IgG titres 
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than after initial vaccination). After the triple-injection boost, titres persisted for 
approximately 6 months at low levels, consistent with the formation of memory. 
Finally, a single booster-injection, applied every 3 months, was able to sustain 
antibody titres, and yielded reversal of antibody titres after approximately 5 
months. 
 
 
Figure 3.7. Long-term kinetics of anti-IL-17A titres in mice receiving repeat 
booster regimens and/or after induction of active psoriasis-like disease in vivo. 
Arrows indicate vaccine injections given to each group by colour code.  Baseline 
immunisation schedule is shown on the bottom with striped arrows. White arrows at the 
top represent 3-monthly single booster shot (n = 4) whereas black arrows at the bottom 
represent triple-injection boost (n = 8) respectively.  
 
These data show that antibody generation in response to the IL-17A vaccine is 
reversible and that antibody titres can be re-boosted either by single-injection or 
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by injection using three monthly regular boosters, or by full triple-injection 
vaccine schedule. Importantly, the data show that endogenous psoriasis-like 
disease with increased local IL-17A release in the skin did not trigger 
endogenous boosting of the anti-IL-17 response. 
 
3.5 Enhancing vaccine responses by pre-DPT injection  
In clinical practice it would be important to induce an anti-IL-17 antibody 
response above a minimal threshold in as many patients as possible. For most 
classical vaccines, however, there is a population of low vaccine responders. In 
recent years evidence has been gathered to suggest that these poor antibody 
responses are driven by the absence of good T cell epitopes within the vaccine 
for these particular individuals. In order to overcome this limitation, the IL-17A 
vaccine used in this thesis has been engineered to genetically incorporate a 
universal T cell epitope. This universal T cell epitope is derived from the tetanus 
vaccine, which is used in all individuals exposed to tetanus. Since tetanus 
vaccination, given as part of the DPT-vaccination, is universally administered in 
most populations, this epitope provides a vaccine-intrinsic immunostimulatory 
adjuvant. Thus, one of the key-target populations with decreased 
responsiveness to vaccines, the elderly, has pre-existing T cell memory to the 
epitope. Such a feature is expected to reduce the fraction of patients making 
poor antibody responses, essentially avoiding the non- or low-responders.  
In order to test whether previous exposure to tetanus vaccination enhances the 
response to the IL-17A vaccine, both young and old mice were immunised with 
DPT (as used in humans) prior to immunisation against IL-17. As shown in 
figure 3.8, pre-vaccination with DPT induced a statistically significant increase in 
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mean antibody titres against IL-17 in the older group of mice. These data 
indicate that the design feature added to the cytomegalovirus-VLP may be able 
to enhance antibody response in recipients of the vaccine.  
 
 
Figure 3.8. The effect of DPT-pre-immunisation on the anti-IL-17A antibody titres 
in 18 months old mice (n = 5 per group) receiving a sub-optimal dose (10μg) of anti-
IL-17A vaccine.  Data shown represent average and standard error of the mean. * p < 
0.05 (T-test) 
 
The group of young mice with DPT-pre-immunisation also showed an earlier 
increase and higher anti-IL-17A titre level compared to those without DPT 
immunisation. However this did not reach statistical significance, most likely due 
to the limited number of animals studied, as shown in figure 3.9. 
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Figure 3.9. The effect of DPT-pre-immunisation on the anti-IL-17A antibody titres 
in 7 months old mice (n = 5 per group) receiving a sub-optimal dose (10μg) of anti-IL-
17A vaccine. Data shown represent average and standard error of the mean. 
 
3.6 Enhancing vaccine responses by blocking IL-22     
IL-22 has been shown to have a potent role in the inflammatory process of 
psoriasis in humans, and as such anti-IL-22 antibodies are used in the 
treatment of IL-22 mediated inflammatory disorders, including psoriasis. Mice 
were injected with anti-IL-22 antibody to determine whether this enhances the 
vaccine or anti-IL-17 antibody. As shown in figure 3.10, a reduction in epidermal 
dorsal skin thickness was demonstrated in the dorsal skin H&E samples. 
However neither the vaccine (p = 0.34) nor the antibody (p = 0.33) caused a 
statistically significant decrease compared to the group with no treatment and 
imiquimod only.  
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Figure 3.10. H&E stained dorsal skin taken from imiquimod-treated mice, and 
mice receiving concurrent anti-IL-17A treatment or vaccinated against IL-17A, 
with concurrent anti-IL-22 knockout as indicated. Left: representative samples, 
shown at 100x magnification. Right: quantification of n = 5 mice per treatment group.  
 
In contrast to the lack of response in the dorsal skin there was a statistically 
significant decrease in the epidermal thickness of the ears of these mice (p = 
0.01), as shown in figure 3.11. Of interest only the vaccine, not the monoclonal 
antibody (p = 0.06), achieved statistical significance in this reduction. However, 
only half the dose of the antibody was given for this test, which could be the 
reason for the difference in reduction. Nevertheless such a gap does not exist in 
the dorsal skin data.  
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Figure 3.11. H&E stained ear taken from imiquimod-treated mice, and mice 
receiving concurrent anti-IL-17A treatment or vaccinated against IL-17A, with 
concurrent anti-IL-22 knockout as indicated. Left: representative samples, shown at 
100x magnification. Right: quantification of n = 5 mice per treatment group. * p< 0.05 in 
a two-sided T-test. 
 
Clinical photographs of the mice were taken at the time of scheduling to show 
phenotypes of the mice. These photographs showed a greater degree of 
erythema and irritation of the dorsal skin for mice with applied imiquimod 
compared with either the vaccine or antibody treatment, as shown in figure 
3.12. 
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Figure 3.12. Clinical photographs of the mice from anti-IL-22 experiment taken at 
time of scheduling. Mice in the imiquimod only group can be seen to have more 
erythematous dorsal skin and ears than that of the other groups in the study. 
 
3.7 Enhancing vaccine responses by formulation with aluminum gel     
To determine whether formulation of the anti-IL-17 vaccine with aluminum gel 
as adjuvant enhances antibody response, this was compared with both the 
regular IL-17 vaccine and IL-17 targeting monoclonal antibody. As shown in 
figure 3.13, ELISA analysis 2 weeks after each time interval shows a 
significantly higher titre level in the group with the formulated vaccine compared 
to the regular vaccine.  
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Figure 3.13. Change in anti-IL-17A titre levels when IL-17 vaccine formulated with 
aluminum gel. Anti-IL-17A titre levels in mice vaccinated without additional adjuvant 
(blue circles) compared to those with adjuvant (white circles).  
 
Despite the significantly higher anti-IL-17A titre levels in all mice with the 
adjuvant, the same significance was not achieved comparing the greater 
reduction of epidermal thickness of the dorsal skin samples with that of the 
unaltered vaccine (p = 0.23). Both the formulated vaccine (p = 0.10) and the 
monoclonal antibody (p = 0.16) failed to reach statistical significance with 
comparison to the imiquimod only group, as shown in figure 3.14.  
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Figure 3.14. H&E stained dorsal skin taken from imiquimod-treated mice, and 
mice receiving concurrent anti-IL-17A treatment, formulated anti-IL-17A vaccine 
or vaccinated against IL-17A, as indicated. Left: representative samples, shown at 
100x magnification. Right: quantification of n = 5 mice per treatment group. Al vaccine 
represents the formulated vaccine with aluminum gel.  
 
Similar to the dorsal skin of these mice the results of the ear sample epidermal 
thickness H&E analysis showed a greater reduction with the formulated vaccine 
compared with the equivalent dorsal skin samples from the unaltered vaccine, 
however this failed to reach statistical significance (p = 0.35). Nevertheless, 
both the vaccine (p = 0.04) and even more so with the formulated vaccine (p = 
0.003) achieved a significant reduction in comparison to the imiquimod only 
group, as shown in figure 3.15.  
  
70 
 
 
Figure 3.15. H&E stained ear taken from imiquimod-treated mice, and mice 
receiving concurrent anti-IL-17A treatment, formulated anti-IL-17A vaccine or 
vaccinated against IL-17A, as indicated. Left: representative samples, shown at 100x 
magnification. Right: quantification of n = 5 mice per treatment group. Al vaccine 
represents the formulated vaccine with aluminum gel. * p< 0.05 in a two-sided T-test. 
 
Clinical photographs of the mice were taken at the time of scheduling to show 
phenotypes of the mice. These photographs showed a greater degree of 
erythema and irritation of the dorsal skin for mice with applied imiquimod 
compared with the vaccine, formulated vaccine or antibody treatment, as shown 
in figure 3.16. Despite shaving at the time of scheduling, many mice had 
overlying hair which made the phenotype more difficult to exhibit a change than 
could be evidenced by the histological analysis. 
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Figure 3.16. Clinical photographs of the mice from formulation of the IL-17 
vaccine with aluminum gel experiment taken at time of scheduling. Mice in the 
imiquimod only group can be seen to have more erythematous dorsal skin and ears 
than that of the other groups in the study. 
 
3.8 Reproducibility and long-term stability of anti-IL-17A vaccine  
Overall, three independent experiments were carried out to determine the 
efficacy of the vaccine. Two of these were carried out with different batches of 
IL-17 vaccine. A third experiment was carried out with the same batch as used 
earlier but after prolonged storage at -200C. Therefore, the sum of these data 
afforded tentative information on the long-term stability of vaccine stored under 
these conditions, as well as the reproducibility of clinical efficacy of the vaccine 
between various batches. Pertinent protocol features of each experiment are 
summarised in the table 3.1.  
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Table 3.1. Summary of key protocol design features and outcomes of IL17VAX 
prototype non-clinical efficacy in vivo studies in mice. For experiments 1 and 2 the 
primary outcome was measured on day 8, for experiment 3 (elimination of IL-22 
signalling) it was measured on day 11. 
Experiment 1 2 3 
Specific 
Aims 
First in vivo efficacy 
test of IL-17 prototype 
Replicate in vivo 
efficacy with 
independent vaccine 
batch 
Assess vaccine 
stability (storage -
200C > 6 months) 
Assess efficacy after 
elimination of IL-22 
effect in imiquimod 
model 
Primary 
Endpoint 
Reduction of ear swelling after challenge with topical imiquimod 
Outcome Percent reduction of ear thickness compared to Imiquimod only: 
 Vaccine: 76% 
Antibody: 73% 
Vaccine: 50% 
Antibody: 60% 
Vaccine: 23% 
Antibody: nil* 
Statistical 
significance 
P < 0.001 (vaccine vs 
control), two-sided t-
test 
P < 0.001 (vaccine vs 
control), two-sided t-
test 
P = 0.005 (vaccine vs 
control), two-sided t-
test 
Safety 
signals 
None, normal weight gain, no discomfort, no clinical distress throughout 
* Anti-IL-17A was administered only on day 1 in experiment 3. 
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The data summarised in table 3.1 confirm that the IL17VAX vaccine is as 
effective as a validated monoclonal anti-IL-17 antibody, as validated using two 
independent vaccine batches, that the vaccine displays significant efficacy after 
storage at -200C for six months, and that efficacy can also be detected in a 
modified imiquimod assay after elimination of IL-22 signalling. Ear thickness 
measurements in each experiment are summarised graphically below in figure 
3.17. It is necessary to mention in figure 3.17 that although the results of the 
day 11 experiment achieves significance in the third experiment, had the 
experiment been discontinued at day 8, as was the case for the other two 
experiments, the vaccine would have failed to achieve a statistically significant 
reduction in ear thickness. Using the day 11 ear thickness measurements may 
therefore show bias towards promoting the efficacy of the vaccine. A later end 
date was used because the methods had a prospective predefined endpoint as 
clinically evident psoriasis like phenotype. At day 8 in the third experiment group 
erythema and scaling were not visible and thus, the mice were scheduled when 
visible at day 11.  
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Figure 3.17. Ear thickness after challenge with imiquimod cream. For summary 
details of the protocols applied, see table 1. Shown are the data for experiment 1 (left), 
experiment 2 (middle), and experiment 3 (right), respectively. Key protocol aspects are 
as follows. Experiment 1: test of vaccine batch 1. Experiment 2: test of independent 
vaccine batch; Experiment 3: test of batch 2 after six months of storage at -200C and 
after disruption of IL-22 signalling. * p < 0.05 in a two-sided T-test.   
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Discussion  
 
The below discussion evaluates the significance of the results of this thesis, as 
well as limitations, considers pertinent published literature, and what future 
studies would be warranted based on the current results. In particular, attention 
is paid to what future steps may be made in line with further pre-clinical and 
clinical trial development. 
 
4.1 Safety of vaccination against interleukin 17  
4.1.1 Specificity and safety    
Evidence is accumulating to support the transition away from the traditional 
view that vaccines act only on their intended target molecule (161). Rather, 
heterologous effects may occur as memory T cells created due to the vaccines 
are able to adapt and target other molecules (162).This can have positive 
outcomes, as is the case of the non-specific outcomes for measles vaccination 
which reduces mortality from diseases other than measles by 45% when given 
at 4.5 months of age. A similar reduction in mortality has been demonstrated for 
other live vaccines such as Bacillus Calmette–Guérin (BCG) (163). DPT 
vaccine - a non-live vaccine, had been shown to have non-specific actions 
which increased mortality from infections other than diphtheria, pertussis and 
tetanus. Nevertheless, further studies and meta-analysis studying this have 
shown the effect to be deleterious (164). Increased mortality from such vaccines 
off target effects is of particular concern in countries with less healthcare 
provisions and higher infection associated mortality rates.  
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Therefore it was important to determine how specific a response was produced 
from the vaccine. The antibody response generated from the IL-17 vaccine was 
highly specific for IL-17A, as no significant antibodies reactive to the most 
closely related isoform, IL-17F, were detectable, as shown in figure 3.2. These 
results are in agreement with those made with another VLP-type IL-17A vaccine 
used to treat inflammatory arthropathy (165). This is important for safety 
consideration, as this result shows the vaccine is targeted in its action and to 
our knowledge does not affect unintended molecules, which could lead to 
potential toxicity in mice. Nonetheless, the non-specific effects of such a 
vaccine ultimately will have to be verified in human studies. The concerns of 
infection from childhood vaccination studies may be less important in psoriasis 
cohorts, as the main treatment group is adults, who are past the childhood 
vaccination schedules. 
 
4.1.2 Treatment associated adverse events  
Therapeutic vaccines based on the VLP technology employed in the IL-17A 
vaccine, but targeted at other self-proteins, have previously been tested in 
humans (147, 148). These clinical studies have not shown any concerning 
safety signals, in particular, no non-specific off-target immune activation. 
Furthermore, existent data have not uncovered evidence of severe vaccine-
related adverse effects in rodents or non-human primates immunised with anti-
IL-17A vaccine.  
No unexpected adverse events were reported in the mice across all 
experiments. The only adverse event, which was to be expected, was erythema 
of the dorsal skin and ears where imiquimod was applied. This was, in fact, a 
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treatment-emergent adverse effect due to TLR7 activation and independent of 
the vaccine. No adverse events were observed with the IL-17 vaccine, or 
formulated IL-17 vaccine with aluminum gel. 
 
4.1.3 Mortality and premature scheduling  
Two mice were scheduled prematurely and a post-mortem was performed on 
both by a veterinary surgeon. One mouse had a swollen abdomen which 
revealed a large liver tumour and the other had a peptic ulcer. Of these mice 
only one mouse was vaccinated with the IL-17 vaccine, a first dose given one 
day before scheduling. Given the short time between vaccine administration 
and scheduling it seems unlikely the vaccine is the cause, as the formation of a 
hepatic tumour in such a timeframe would be unheard of. Therefore, the cause 
of these outcomes remains uncertain but is extremely unlikely to be due to 
vaccination. 
 
4.1.4 Prolonged exposure and safety record  
Immunisation of human patients with auto-vaccines using the same vaccine 
technology and immunisation of rodents and non-human primates with the IL-
17A vaccine have consistently shown that the production of anti-IL-17 is 
reversible and continued antibody production is dependent on booster 
vaccination (166). The precise kinetics of reversal has not been studied in 
humans to date but no VLP-based vaccine has been shown to elicit antibody 
titres persisting beyond six months in the absence of follow-up booster (166).  
The long-term kinetics experiment demonstrates the safety of the vaccine over 
a 58 week period. Currently available data of the prototype IL-17 vaccine 
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studied in mice also shows reversibility, as shown in figure 3.7. These data 
indicate that vaccination against IL-17A is unlikely to trigger irreversible long-
term neutralising antibodies in vaccine recipients. Data shows that even with 
repeated exposure to the vaccine there are no increased risk of treatment 
associated adverse events or mortality in the mice. Moreover, one group of 
mice given an endogenous boost with imiquimod did not respond differently to 
those without an endogenous boost, suggesting flares in the disease would not 
significantly raise the titre levels, as shown in figure 3.8. 
 
4.1.5 Safety of anti-IL-17 biologic agents  
Data available from published clinical trials of IL-17 targeting monoclonal 
antibodies reveals more than 20,000 patient years of long-term inactivation of 
IL-17. These have shown for the three monoclonal antibodies, seckunimab, 
ixekizumab and brodalumab, that no concerning safety worries are apparent 
(167). Across the different studies dose-dependent candida infections, which 
were severe enough to be treatment limiting, represent the main adverse effect 
experienced. Moreover, there have been no reported safety concern signals in 
patients with other conditions being treated with anti-IL-17 therapies. 
 
4.2 Treatment rationale and efficacy of the vaccine   
4.2.1 Efficacy of anti-IL-17 biologic agents  
The treatment of moderate to severe psoriasis has been revolutionised by 
monoclonal antibodies and recombinant proteins. The chief limitations of 
currently licensed anti-TNF and anti-IL-12/23p40 biologics are systemic 
immunosuppression leading to increased risk for severe infection, in particular 
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mycobacterial infection such as tuberculosis, as well as the lack or loss of 
efficacy in a subset of patients. IL-17 targeting monoclonal antibodies bear the 
prospect of overcoming these limitations. However, the complex and 
demanding manufacturing process of biologics translates into exceedingly high 
treatment costs, which is increasingly limiting access of effective treatment for 
patients. Injection of a monoclonal antibody represents a form of passive 
vaccination. Replacing this by active vaccination, in order to elicit the generation 
of antibodies by the vaccinated person, bears the potential of dramatically 
reducing treatment cost and therefore opening access to effective disease 
control to many more patients. 
 
4.2.2 Dose response   
Vaccines can produce measurable effects even at very low doses. In this thesis 
doses as low as 0.5g of IL-17 vaccine were shown to produce measureable 
anti-IL-17 titre levels. In addition, the vaccine shows a dose response effect with 
increasing efficacy with dose increase from 0.5g, as shown in figure 3.1 (in the 
figure labelled with equivalent microliter dosing amounts). The decrease in 
efficacy for the 5.0g group may be attributable to a sampling error as only a 
small number of mice (n = 4) were used per group and one mouse in the 2.5g 
group had a significantly higher titre than the other three mice in that group. 
 
4.2.3 Storage and handling  
Preventing loss of vaccine potency is becoming an increasingly important 
consideration as more expensive vaccines are introduced. Several factors 
pertinent to the storage and handling of vaccines are important to maintain 
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potency and maximise shelf life, including correct storage temperatures and 
minimising freeze-thaw reactions (168). Freeze-thaw reactions have not been 
thoroughly studied however Petrakis showed that as few as one freeze-thaw 
reaction significantly reduced serum IgG and IgM levels to below 25% of pre-
freezing levels (169). Instability of antibody levels following freeze-thaw 
reactions are thought to occur due to protein denaturation. In aqueous 
environments, proteins normally fold spontaneously in such a configuration that 
their hydrophobic side chains are encased by polar chains with a surrounding 
bulk hydration layer. Freezing disrupts this bulk hydration layer rendering it 
inactive. Subsequent unfolding allows hydrophobic reactions to occur, which 
denatures the protein (170).  
Despite being stored at suboptimal temperature of -200C, as opposed to -800C, 
the vaccine showed excellent long-term stability, generating antibody response 
after greater than six months of storage at this temperature. Freeze-thaw 
reactions were minimised by aliquoting the vaccine into smaller volumes 
suitable for injections prior to long-term storage. Across all the experiments, IL-
17 vaccine injected into mice never underwent greater than two freeze-thaw 
reactions. Nevertheless, the experiment evaluating the use of the vaccine with 
IL-22 used vaccine which had been stored for over 6 months at -200C. 
Decreased efficacy was noted in this experiment which could be a result of loss 
of stability possibly due to retained overall titre but decreased titre of 
neutralising antibodies by antigen degeneration. This could have been studied 
to determine if this was the cause using neutralising assay of the sera.   
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4.2.4 Batch-to-batch consistency  
To confirm the reliability of the manufacturing process demonstration of batch-
to-batch consistency has become a mandatory step in vaccine development. 
Many factors can interfere with the antigen content of the vaccine resulting in 
different immune response of the final product, including different manufacturing 
processes and interactions with adjuvants added to the final vaccine product. 
Therefore, demonstration of batch consistency is necessary should the 
manufacturer wish to gain a licence for their vaccine (171, 172). 
Two independent batches of the IL-17 vaccine were supplied by the Jenner 
Institute. Both batches demonstrated significant ability to reduce epidermal 
thickness of the ears and dorsal skin, as shown in table 3.1. In addition, mice 
injected with both batches of the vaccine had high anti-IL-17 titre levels post 
vaccination. These findings provide strong evidence of the efficacy of the 
vaccine, in addition to the manufacturing process in producing consistent 
vaccine batches.   
 
4.3 Modification of vaccine responses by pre-DPT injection    
Conventional vaccines often suffer from varied efficacy especially in elderly 
patients, a phenomenon sometimes called immunosenescence. 
Immunosenescence has an effect on both the innate and adaptive immune 
system. Defects and deficiencies of the antigen presenting cells of the innate 
immune system results in diminished activation of the cells of the adaptive 
immune response (173).  Approaches to overcome these limitations in the 
elderly have been trialled for the influenza vaccine, namely higher doses and 
intradermal delivery, and have shown improved vaccination response (174, 
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175). DTP vaccine is included in the UK childhood immunisation schedule 
beginning from 2 months of age, and has also been introduced for pregnant 
mothers (176). Studies have also shown it to be safe to administer to patients 
over the age of sixty-five (177). 
The IL-17 vaccine undergoing pre-clinical evaluation was modified in the 
manufacturing process such that prior vaccination against tetanus (performed in 
close to 100% of the population) acts as a vaccine booster. The results of the 
thesis show that in the older group of mice, aged 7-8 months at the beginning of 
the experiment, this was the case, as shown in figure 3.8. There was a 
significant rise in anti-IL-17 titre from as early as 2 weeks after triple induction 
scheme, which continued to be the case until 22 weeks, without the need for 
further DPT injections. Notably this was the case despite sub-optimal dosing 
with a vaccine dose of only 10l per vaccination, equivalent to only 0.5g. This 
small vaccine dose, in conjunction with the limited number of mice involved in 
the experiment (n = 5) may explain why the same experiment in the younger 
group of mice did show a rise in titre, but not significantly higher than those 
without prior DPT vaccination, as shown in figure 3.9. Provided this is one of the 
intended benefits added into the manufacturing stage, repeating these 
experiments with a higher dose of IL-17, suggested 2.5g, and/or larger 
numbers of mice would be useful to see if this yields consistently higher titre. 
 
4.4 Modification of vaccine responses by blocking IL-22     
IL-22 is a cytokine produced from Th1, Th17 and Th22 subsets. IL-22 inhibits 
terminal differentiation of keratinocytes and can induce epidermal alterations 
found in psoriasis. Moreover, elevated levels of IL-22 mRNA have been 
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identified in psoriatic skin lesions compared with healthy skin (178). The use of 
IL-22 neutralising antibodies has been shown to prevent the development of 
psoriatic lesions, reduce acanthosis and decrease expression of Th17 cells 
(179). Van Belle et al demonstrated that psoriasiform reactions caused by daily 
imiquimod application were almost absent in mice deficient in IL-22 or treated 
with anti-IL-22 antibodies. Studies investigating the mechanism of action of the 
imiquimod assay show it appears to harbour a synergistic effect of IL-17 and IL-
22 (180). Therefore the IL-17 blocking effect could be stronger after eliminating 
IL-22. These mice also showed decreased expression of chemotactic factors 
such as CXCL3 and biomarkers such as S100A8 which reflect 
hyperproliferative responses of keratinocytes (180). Fezakinumab is a 
monoclonal antibody targeting IL-22 which has completed phase II trials for 
rheumatoid arthritis and a phase I trial investigating subcutaneous and 
intravenous routes of administration. Despite this the results of these trials 
conducted in 2010 were never published, suggesting this may not provide 
optimal therapy for psoriasis patients (181). 
The results of inhibition of IL-22 activity obtained in this thesis were 
inconclusive. Reduction in dorsal skin samples treated with IL-17 vaccine after 
pre-elimination of IL-22 signalling by injection of anti-IL-22, failed to reach 
statistical significance, as shown in figure 3.10 despite a significant decrease in 
analogous ear thickness samples, as shown in figure 3.11. Of note, the anti-IL-
17 antibody combined with the anti-IL-22 antibody also failed to achieve a 
statistically significant decrease in dorsal skin thickness.  Nevertheless, this 
group of mice only received half the dose of the anti-IL-22 antibody therefore 
the results must be treated cautiously. Given the statistically significant 
decrease in epidermal ear thickness however, this is an approach which merits 
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further investigation in NHP studies. No adverse events were associated with 
additional blockade of IL-22. Moreover, the lack of toxicity seen in the mice with 
this additional antibody is encouraging from a safety point of view of targeting 
greater than one pro-inflammatory cytokine. 
 
4.5 Modification of vaccine responses by adjuvants  
Adjuvants are components of a vaccine capable of enhancing or shaping 
antigen-specific immune responses. Development of adjuvant therapy in 
vaccines balances improving immune responses without compromising safety 
by selectively adding well-characterised molecules or formulations (182). 
Advantages of using adjuvants include dose sparing, less immunisations, 
broadening of vaccine response and rapid response to pathogens. There are 
many adjuvants used, which can be divided into organic and non-organic, but 
the most commonly used are aluminium salts, principally aluminium hydroxide 
and aluminium phosphate (183). Aluminium potentiates the immune response 
as a powerful pro-oxidant. The biologically reactive form of aluminium is 
primarily the Al3+ ion which is avidly bound by oxygen and fluoride-based 
functional groups. Aluminium potentiates the activity of extracellular adenosine 
triphosphate (ATP), which is implicated in the release of pro-inflammatory 
cytokines, by two possible mechanisms. One mechanism involves prolonging 
the lifetime of the nucleotide-receptor complex and the other mechanism via 
reducing ATP hydrolysis by ectonucleotidases (184).  
Enhancement of the vaccine with aluminum gel raised the anti-IL17 titre 
significantly after each vaccination point in all mice (n = 5) tested, as shown in 
figure 3.13. Despite this considerable rise in titre, the standard vaccination and 
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formulated vaccine failed to achieve a statistically significant reduction in 
epidermal dorsal skin relative to the positive control group, as shown in figure 
3.14. However, a significant reduction was demonstrated in the ear epidermal 
thickness, as shown in figure 3.15. The formulated vaccine did show greater 
reduction in epidermal thickness, of both ear and dorsal skin samples, than the 
standard vaccine, and also compared to the anti-IL-17 antibody. It is unclear 
why none of the three treatment options failed to significantly reduce the dorsal 
skin epidermal thickness in this experiment. It is possible this could be due to a 
decrease in neutralising antibodies as a result of antigen degradation after long-
term storage. The majority of B cell epitopes are conformational epitopes 
created by multiple protein loops acting as a 3D surface. These are lost if the 
protein is denatured, as could have occurred here. However peptide epitopes 
could have been recognised by T cells, which would give rise to high ELISA 
titres but no neutralising titre by binding to epitopes buried deep inside the 
native protein. It is unlikely due to long-term storage of the vaccine at -200C as 
this was stored for less time than in the IL-22 blocking experiment which 
achieved significance for ear epidermal thickness reduction after 6 months of 
long-term storage at this temperature. Moreover, this would not account for the 
fact the antibody similarly did not cause a significant reduction, as this was only 
bought in 1 week before starting the experiment. The aluminum gel was only 
mixed with the vaccine before injection into the mice, thus it was never stored in 
less than room temperature as instructed. A possible explanation might be too 
much imiquimod application onto the dorsal skin and ears, however the same 
amount (one sachet) was used in previous experiments and did not cause this 
problem. With this in mind formulation of the vaccine with aluminum gel 
nevertheless did reduce epidermal thickness. Although the reduction was not 
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statistically significant, the lack of previously significant data with this 
experiment suggests it may be worth repeating in another mouse group to 
identify whether it would be of benefit before NHP studies.   
 
4.6 Further studies   
The current study has been conducted in accordance with the 3Rs principle - 
replacement, reduction and refinement - designed to minimise the number of 
animals used in testing while still allowing enough to yield statistically significant 
data. The results of this thesis support continuation of studies into a NHP study.  
Careful consideration of NHP species protein sequence identity and similarity of 
IL-17A to the human equivalent would be most helpful for evaluating both 
efficacy, and more importantly, toxicity of the vaccine. Cynomolgus monkey are 
an example of a species with similarities to humans in these sequences and 
have been used successfully for NHP studies of medications in the past (185).  
NHP studies could be used to simultaneously assess toxicity and the 
pharmacodnymanic action of the vaccine as neutralising anti-human IL-17 
antibodies also neutralise monkey IL-17 (186). 
Should the vaccine continue to provide promising safety and efficacy results in 
NHP studies progression would follow into human clinical trials. Vaccine 
development follows the same four phases of clinical trials as other therapeutic 
agents (187). Successful outcomes at clinical trial stages could potentially lead 
to clinical use of the vaccine for psoriasis patients in the future. 
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4.7 Limitations  
4.7.1 Longevity of mice compared to humans   
The lifespan of mice represents a limitation in monitoring the long-term kinetics 
and repeated booster effects of the IL-17 vaccine. The life expectancy of 
C57Bl/6j mice is approximately two years which is significantly shorter than 
human lifespan (188). Therefore only three repeat boosters were given to mice 
in this thesis, where in human clinical practice the intended use would most 
likely extend beyond this, given psoriasis is a chronic incurable condition, 
potentially continuing treatment over many years. It cannot therefore be seen if 
further boosters would significantly raise titre or continue to have the same 
effect. Moreover, the long-term titre levels without boostering and the 
development of late onset adverse events were not able to be studied. 
Nevertheless, had this study been a human clinical trial, these studies do not 
often extend beyond a two year period. A recent study developed a multiple 
regression model to identify the mean overall length from 14,319 completed 
Phase I, II or III drug intervention trials at 21.4 months. This was due to factors 
including cost and patient compliance (189). Such a short trial length would 
make studying these long-term effects of this vaccine difficult to analyse until 
post surveillance monitoring stages. Taking this into account, the 58 weeks of 
safety and efficacy data from the long-term kinetics study seems a good proxy 
marker before progression onto NHP studies.  
 
4.7.2 Inbred strains of mice   
Inbred strains examine only the phenotype of a single genotype that may not be 
representative of the species. This can lead to misleading results and can be 
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overcome by two potential methods: using multiple different species of inbred 
stock or by using outbred stocks. Experiments need to factor in the significance 
of phenotypic differences between inbred strains. Strains may differ in 
characteristics that are not related to the phenotype under investigation, but 
may indirectly influence experimental results.  An example would be C3H mice 
become blind in early adulthood due to a mutation in their strain, which would 
impact upon behavioural analysis studies requiring sight (190). The C57Bl/6j 
strain of mice are commonly used to investigate psoriasis and other diseases, 
however results could differ if other strains were used. For example Balb/c 
inbred strain have been used extensively in imiquimod induced psoriasis 
models and the effects of the vaccine could have been studied in these mice 
and potentially different results yielded (191, 192).  Inbred studies are generally 
preferred because they require fewer mice on average to produce statistically 
significant results. Outbred stocks introduce genetic heterogeneity into the 
subjects being researched, offering a greater range of subjects more 
representative of a diverse human population. However, outbred stocks have 
several disadvantages compared to inbred strains including the genotype of 
individual mice is unknown, the extent of genetic variation in the stock is usually 
unknown and the mice are genetically labile (193). 
To introduce even greater diversity different animal species could be used. 
Studies testing medications for psoriasis have been completed in rabbits in the 
past to evaluate potential safety concerns (194). Rabbits offer advantages for 
studies in that they are licensed under small animals, providing a more 
economical alternative to larger animals such as dogs or pigs. In addition they 
are widely bred and docile animals, making them easy to handle (195). Testing 
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the response of the vaccine in rabbits could offer further evidence to support the 
safety of the vaccine before considering NHP and human studies thereafter.  
 
4.7.3 Use of only one disease model to induce psoriasis like reaction  
This study used only one disease model to simulate psoriasis, the imiquimod 
application model. This represents a potential limitation as psoriasis does not 
naturally occur in mice and thus, using greater than one method could reduce 
any important phenotype differences that are absent from the imiquimod model. 
In addition, different brands of imiquimod have been shown to have different 
effects. A study by Luo et al (145), showed Aldara cream, the same brand of 
imiquimod used in this thesis, showed more characteristic histology of psoriasis 
as opposed to other brands. However, other brands or dosing regimens of 
imiquimod application could have been used to demonstrate effectiveness in 
various psoriasiform lesions.  
A variety of transgenic and gene knockout mouse models have been created 
which simulate psoriasis phenotype features. The majority of these methods 
increase expression or knockout specific genes directed to the basal layer using 
promoters for keratin genes KRT5 or KRT14, or involucrin promoter sequences. 
Moreover manipulation of the STAT3 pathway, key to wound healing and 
activated in psoriasis, has been shown to induce acanthosis, parakeratosis and 
loss of the granular layer of mice (196). Targeting growth factors involved in 
psoriasis pathology, such as VEGF, has also been shown to result in 
characteristic inflammatory changes of psoriasis lesions (197). 
Xenotransplantation of psoriatic skin lesions into immunocompromised mice 
offers the closest similarity to human psoriasis with regard to genetic and 
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histological changes (198). Nevertheless, this is an expensive method and 
takes longer to achieve desired results than the imiquimod method.  
Using at least one of the above methods for an additional experiment could 
provide further support for the efficacy of the vaccine to reduce psoriasis like 
reactions before progressing to NHP studies. Despite this, the role of IL-17 in 
disease pathogenesis of psoriasis is well recognised and the imiquimod model 
importantly induces the IL-17/IL-23 axis. In addition a similar IL-17 targeting 
vaccine has been shown to have effect on other IL-17 mediated disorders, 
namely RA and MS (165).  
 
4.7.4 No neutralising antibodies tested  
A potential limitation may be having not identified whether anti-drug antibodies 
were present in the serum of the mice treated with the IL-17 antibody. High 
levels of these have been shown in humans treated with biologics, and some 
studies have associated high levels of these antibodies with decreased efficacy 
of the treatment (199). High levels of the serum neutralising antibodies might 
explain why some mice responded better to the antibody treatment than others. 
Similar neutralising antibodies against the IL-17 vaccine could also be tested for 
and might provide a reason for different responses from mice given identical 
therapies. To overcome such limitations, in clinical practice patients are treated 
with supplemental non-biologic therapies such as methotrexate. Adding 
supplemental therapies at this stage would most likely complicate rather than 
aid the project.    
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4.8 Summary   
In summary, the IL-17A vaccine is a vaccine designed to elicit the production of 
antibodies blocking the function of interleukin 17A, which is identical to the 
target blocked by monoclonal antibodies already in clinical use in the treatment 
for psoriasis. Pre-clinical data in rodents and non-human primates suggest the 
IL-17A vaccine is capable of eliciting high-titre anti-IL17A as well as blocking the 
development of IL-17A-mediated inflammatory disease. By increasing the 
number of mice used per experiment a greater statistical significance reduction 
in epidermal thickness could have been shown for the vaccine group, 
particularly for the later experiments of IL-22 blockade, DPT pre-immunisation 
and formulation of the vaccine. This was not done due to the observed effect 
size with the second experiment - the primary efficacy experiment - which 
yielded highly statistically significant data. Thus in order to comply with the 
principle of the 3Rs, similar numbers of mice were used as were for the primary 
efficacy experiment. Clinical trials of anti-IL-17A monoclonal antibodies have 
demonstrated that neutralising IL-17A is safe and sufficient to treat moderate-to-
severe psoriasis. The benefit of replacing monoclonal antibodies by active 
vaccination is that this approach would vastly decrease treatment cost and 
could ultimately provide access to treatment to a much greater number of 
patients. An added benefit is that successful proof-of-concept would also be 
applicable to development for other monoclonal antibodies targeting cytokines. 
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Conclusion  
 
This thesis details the preclinical evaluation of an IL-17A vaccine for psoriasis. 
The results show the vaccine to be as effective a treatment option as IL-17 
targeting monoclonal antibodies. H&E histology data shows a statistically 
significant reduction in mouse dorsal skin and ear epidermal thickness 
compared to groups with imiquimod application only. Long-term kinetic studies 
showed that antibody generation in response to the IL-17A vaccine is reversible 
and can be re-boosted by single injection of booster or full vaccination 
schedules. Moreover, endogenous psoriasis-like disease with increased release 
of IL-17A in the skin does not trigger an endogenous boosting of the anti-IL-17 
response. Another safety issue was addressed with the vaccine proving to be 
highly specific as no significant antibodies reacted to the most closely related 
isoform IL-17F. Tentative data shows that the IL-17 vaccine response, 
particularly in older mice, may be enhanced by pre-vaccination with the 
common DPT vaccination. Furthermore, the vaccine has been shown to 
effectively minimise imiquimod applied ear thickness after storage at -200C for 
six months, and in two independent batches. These results offer potential for 
replacing passive immunisation by an active vaccination against IL-17A. In 
addition to significantly reducing treatment cost, this approach could potentially 
be advantageous in other important areas such as, ease of dosing, minimising 
treatment related staffing requirements, and avoidance of anti-drug antibodies. 
Moreover, if effective, an IL-17A vaccine has the potential to provide improved 
treatment access for other common conditions amenable to anti-IL-17A 
treatment, including rheumatoid arthritis and multiple sclerosis. To progress 
93 
 
towards use in clinical practice, the next step for the development of the IL-17A 
vaccine would be a non-human primate study, before beginning clinical trials.   
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